001-MCS-40-106_RD-03 (18.0) / Saved on: 10 Jul 2019
Clinical Trial Protocol
TITLE PAGE
Document Number: c29492723-[ADDRESS_1154832] how taking BI 1015550 for 12 weeks affects lung function in people with idiopathic pulmonary fibrosis (IPF).
Clinical PhaseII
Clinical Trial Leader
Tel: Fax: 
Email: 
Coordinating Investigator
[CONTACT_7626]: Fax : 
Version and Date Version: 4.0 Date: 09 Sep 2020
Page 1 of 118
Proprietary confidential information.
!!2020 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permissi on.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 2 of 118
Proprietary confidential information © [ADDRESS_1154833]-03 (18.0) / Saved on: 10 Jul 2019CLINICAL TRIAL PROTOCOL SYNOPSIS
Company nameBoehringer Ingelheim
Protocol date 17 Feb 2020
Revision date 09 Sep 2020
BI trial number 1305-0013
Title of trial A randomised, double-blind, placebo-controlled parallel group studyin IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 taken orally.
Coordinating 
Investigator
[CONTACT_7626]: 
Fax :
Trial site(s) Multi-centre trial conducted in approximately 20 countries
Clinical phase II
Trial rationale The purpose of this trial is to demonstrate proof of concept of clinical activity of BI 1015550 on the change of Forced Vital Capacity (FVC)between baseline and [ADDRESS_1154834] of care (SoC), which may or may not include currently approved antifibrotic treatments (nintedanib or pi[INVESTIGATOR_7735]). FVCchange from baseline will be used to generate sufficient evidence of efficacy in the subpopulation on no background antifibrotic treatment, to inform the phase III program.
Trial objective(s) To investigate the efficacy of BI 1015550 18 mg b.i.d compared to 
placebo based on the change from baseline in FVC.To investigate the safety and tolerability of BI 1015550 in overall trial population.
Trial endpoints The primary endpoint is the change from baseline in FVC at 12 weeks(in mL).The secondary endpoint is the Percentage of patients (%) N with Treatment Emergent Adverse Events (TEAE).
Trial design Double-blind, placebo controlled, parallel design of 2 groups over 12 weeks.
Total number of 
patients randomisedApprox. 150 (min 120)
Number of patients on Approx. 100 in BI 1015550 18 mg b.i.d. group

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 3 of 118
Proprietary confidential information © [ADDRESS_1154835]-03 (18.0) / Saved on: 10 Jul 2019each treatment Approx. 50 in placebo group
Diagnosis IPF patients either treated with antifibrotic treatment or not.
Main in- and exclusion 
criteriaInclusion criteria :
∀Patients aged ≥40 years.
∀IPF diagnosis confirmed by [CONTACT_9559].
∀FVC ≥ 45%.
∀DLCO ≥25% and<80%.
∀Either stable treatment with antifibrotics for at least [ADDRESS_1154836] 8
weeks prior to Visit 1.
Exclusion criteria : 
∀Relevant airways obstruction (pre-bronchodilator FEV1/FVC 
< 0.7) at Visit 1.
∀Acute IPF exacerbation within 4 months prior to screening and/or during the screening period.
∀Lower respi[INVESTIGATOR_832032] 4 weeks prior to Visit 1 and/or during the screening period.
∀Any suicidal behaviour in the past 2 years.
∀Any suicidal ideation of type [ADDRESS_1154837] 3 months or at Visit 1.
∀Baseline condition or medical history of vasculitis.
∀
Confirmed infection with SARS-CoV-[ADDRESS_1154838](s) BI 1015550
dose 18 mg b.i.d (36 mg daily)
mode of 
administrationOral
Comparator product(s) Placebo
dose Matching
mode ofadministration Oral
Duration of treatment 12 weeks
Statistical methods The purpose of this trial is to demonstrate proof of concept of clinical 
activity of BI 1015550 on the primary endpoint. For the proof of concept an evaluation of a minimum relevant additional benefit of BI 1015550 compared to placebo is conducted. Hereby, the posterior probability of the difference in change from baseline in FVC between BI 1015550 and placebo will be evaluated for different boundary values.The primary endpoint change from baseline in FVC at week 12 will be evaluated separately in the patient group with antifibrotic treatment and in the patient group with no antifibrotic treatment.
To account for the repeated nature of the data and the covariates in 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 4 of 118
Proprietary confidential information © [ADDRESS_1154839]-03 (18.0) / Saved on: 10 Jul 2019the model, MMRM analysis will be carried out for change from baseline of FVC after 12 weeks of treatment in each patient group.The adjusted mean change from baseline (and the related standard error) will be calculated for each group and will be used for the Bayesian borrowing approach.
The analysis will include the fixed, categorical effect of treatment at 
each visit, and the fixed continuous effects of baseline FVC at each visit. Visit will be treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 5 of 118
Proprietary confidential information © [ADDRESS_1154840]-03 (18.0) / Saved on: 10 Jul 2019FLOW CHART
Trial Periods Screening Randomised Treatment Follow 
Up**
Visits 1 2 3 4 5 6 – End of 
Treatment7 - End 
of Trial
Weeks D 1* 2 4 8 12
EoT + 1 
week
Days -3011 15 29 57 85 EoT + 
7d
Time window for visits -14/+23 
days±3
days±7
days±7
days-7/+4
days+3 days
Informed consent2X
Demographics X
Medical history X
Physical examination X X X X X X X
Vital signs*** X X X X X X X
Weight X X X X X X X
Height X
Safety laboratory tests3XX X X X X X
12 lead-ECG4XX X X
Review of in-/exclusion criteria X X
Randomisation X
Dispense trial drugs X X X
Administer trial drugs X X X X X
Return trial drugs X X X X
X
Spi[INVESTIGATOR_038] (FEV1, FVC)6XX X X X X
C-SSRS7XX X X X X X
 
 XX X
HRCT9X
DLCO6XX X X
 X
 X
Optional 24hr Cough assessment 
substudy12XX
IRT call/notification X X X X X
All AEs/SAEs/AESIs**** X X X X X X X
Compliance check X X X X
Concomitant therapy X X X X X X X
Completion of patient participation X
1. Visit 1 (screening) is expected to be conducted in the 30 days prior to Visit 2 (randomisation), considering the time for 
HRCT central review. This period may be extended up to 44 days in case of administrative issue (eg result from HRCT 
central reading not available). If Visit [ADDRESS_1154841] to be screen failed.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 6 of 118
Proprietary confidential information © [ADDRESS_1154842]-03 (18.0) / Saved on: [ADDRESS_1154843] at Visit 1. Informed consent (IC) needs to be signed before any procedure related to the trial is 
performed, including HRCT review. All adverse events (AEs) and concomitant therapi[INVESTIGATOR_014] (CTs) from the day of signing 
informed consent have to be recorded.
3. Safety laboratory parameters will be evaluated at each visit, pre dose. This will include blood and urine collection.
4. All ECGs will be performed pre dose.5.  
 
6. Order of lung function measurements: 1. Spi[INVESTIGATOR_832033]; 2. DLCO. Measurements have 
to be 
performed at the same time each visit ± 90 min (reference time at Visit 2).
7. At Visit 1, the C-SSRS version to be used is the screening one. At all other Visits, starting at Visit 2, the version of C-
SSRS to be used is the version “since last Visit”.
8.  
 
9. Review of high resolution computer tomography (HRCT). Central review: a historical HRCT not older than 12 months 
should be sent; only if the patient does not have a HRCT within [ADDRESS_1154844] to sign a separate informed consent at Visit 2.
(*) Day of Randomisation / Day of first intake of randomised medication.
(**) Patients who discontinue trial treatment prematurely should still follow the trial schedule, if possible, please see 
section 3.3.4 .
(***) Measurements of vital signs should precede blood sampling 
(****) After the EoTrial visit (=individual patient’s end of the trial) the investigator should report only any cancers of new histology and exacerbations of existing cancer, trial treatment related SAEs and trial treatment related AESIs of which the 
investigator may become aware of and only via the BI SAE form, please see section.[IP_ADDRESS].1 .

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 7 of 118
Proprietary confidential information © [ADDRESS_1154845]-03 (18.0) / Saved on: [ADDRESS_1154846] Period ........................................................................................ 16 1.2.4
Data from non-clinical studies ........................................................................... 16 1.2.5
Data from clinical studies................................................................................... 18 1.2.6
1.3 RATIONALE FOR PERFORMING THE TRIAL ......................................... 18
1.4 BENEFIT - RISK ASSESSMENT..................................................................... 19
Benefits................................................................................................................. 19 1.4.1
Risks ..................................................................................................................... 20 1.4.2
Discussion............................................................................................................. 23 1.4.3
2. TRIAL OBJECTIVES AND ENDPOINTS...................................................... 25
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS........ 25
Main objectives.................................................................................................... 25 2.1.1
Primary endpoints............................................................................................... 25 2.1.2
Secondary endpoint............................................................................................. 25 2.1.3
[IP_ADDRESS] Safety endpoints
.................................................................................................... 26
3. DESCRIPTION OF DESIGN AND TRIAL POPULATION......................... 27
3.1 OVERALL TRIAL DESIGN............................................................................. 27
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP........................................................................................... 27
3.3 SELECTION OF TRIAL POPULATION ....................................................... 28
Main diagnosis for trial entry ............................................................................ 29 3.3.1
Inclusion criteria ................................................................................................. 29 3.3.2
Exclusion criteria ................................................................................................ 30 3.3.3
Withdrawal of patients from treatment or assessments.................................. 31 3.3.4
[IP_ADDRESS] Discontinuation of trial treatment ......................................................................... 32

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 8 of 118
Proprietary confidential information © [ADDRESS_1154847]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].3.4.2 Withdrawal of consent to trial participation ......................................................... 32
[IP_ADDRESS] Discontinuation of the trial by [CONTACT_456] ........................................................... 33
4. TREATMENTS................................................................................................... 34
4.1 INVESTIGATIONAL TREATMENTS ........................................................... 34
Identity of the Investigational Medicinal Products.......................................... 34 4.1.1
Selection of doses in the trial and dose modifications...................................... 35 4.1.2
Method of assigning patients to treatment groups........................................... 36 4.1.3
Drug assignment and administration of doses for each patient...................... 37 4.1.4
Blinding and procedures for unblinding........................................................... 38 4.1.5
[IP_ADDRESS] Blinding................................................................................................................. 38
[IP_ADDRESS] Unblinding and breaking the code ........................................................................ 38
Packaging, labelling, and re-supply................................................................... 38 4.1.6
Storage conditions............................................................................................... 38 4.1.7
Drug accountability............................................................................................. 39 4.1.8
4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS ................................................................................................ 39
Other treatments and emergency procedures .................................................. 39 4.2.1
Restrictions .......................................................................................................... 40 4.2.2
[IP_ADDRESS] Restrictions regarding concomitant treatment ...................................................... 40
[IP_ADDRESS] Restrictions on diet and life style.......................................................................... 41
[IP_ADDRESS] Contraception requirements .................................................................................. 41
4.3 TREATMENT COMPLIANCE ........................................................................ 41
5. ASSESSMENTS.................................................................................................. 42
5.1 ASSESSMENT OF EFFICACY........................................................................ 42
FVC ...................................................................................................................... 42 5.1.1
DLCO ................................................................................................................... 42 5.1.2
5.2 ASSESSMENT OF SAFETY............................................................................. 44
Physical examination .......................................................................................... 44 5.2.1
Vital signs............................................................................................................. 44 5.2.2
Safety laboratory parameters ............................................................................ 44 5.2.3
Electrocardiogram Recording ........................................................................... 46 5.2.4
Suicidal risk assessed by [CONTACT_941] C-SSRS................................................................ 47 5.2.5
Assessment of adverse events............................................................................. 48 5.2.6
[IP_ADDRESS] Definitions of AEs ................................................................................................ 48
[IP_ADDRESS] Adverse event collection and reporting ................................................................ 51

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 9 of 118
Proprietary confidential information © [ADDRESS_1154848]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].5 BIOBANKING .................................................................................................... 55
Methods and timing of sample collection.......................................................... 55 5.5.1
5.6 OTHER ASSESSMENTS................................................................................... 55
24 hr Cough measurement (substudy at dedicated sites only)........................ 55 5.6.1
5.7 APPROPRIATENESS OF MEASUREMENTS.............................................. 55
6. INVESTIGATIONAL PLAN............................................................................. 57
6.1 VISIT SCHEDULE............................................................................................. 57
6.2 DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS ................. 57
Screening period.................................................................................................. 58 6.2.1
Treatment period ................................................................................................ 59 6.2.2
Follow-up period and trial completion.............................................................. 61 6.2.3
Optional substudy ............................................................................................... 62 6.2.4
7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
............................................................................................................................... 63
7.1 NULL AND ALTERNATIVE HYPOTHESES ............................................... 63
7.2 PLANNED ANALYSES..................................................................................... 63
General considerations ....................................................................................... 63 7.2.1
Primary endpoint analyses................................................................................. 64 7.2.2
[IP_ADDRESS] Prior derivation ..................................................................................................... [ADDRESS_1154849] access to source data and documents..................................................... 75 8.3.2
Storage period of records ................................................................................... 76 8.3.3
8.4 EXPEDITED REPORTING OF ADVERSE EVENTS .................................. 76
8.5 STATEMENT OF CONFIDENTIALITY AND PATIENT PRIVACY........ 76

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 10 of 118
Proprietary confidential information © [ADDRESS_1154850]-03 (18.0) / Saved on: 10 Jul 2019Collection, storage and future use of biological samples and corresponding 8.5.1
data ....................................................................................................................... 76
8.6 TRIAL MILESTONES....................................................................................... 77
8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL ................................... 77
9. REFERENCES.................................................................................................... 79
9.1 PUBLISHED REFERENCES............................................................................ 79
9.2 UNPUBLISHED REFERENCES...................................................................... 81
10. APPENDICES ..................................................................................................... 82
10.2 COLUMBIA SUICIDAL SEVERITY RATING SCALE (C-SSRS) ............. 97
10.3 DLCO ................................................................................................................. 103
 
10.5 ELIGIBILITY CONFIRMATION OF IPF DIAGNOSIS
............................ 105
10.6 CREATININE CLEARANCE......................................................................... 106
10.7 EQUIVALENT DOSES OF CORTICOSTEROIDS..................................... 107
10.8 RESTRICTED MEDICATIONS TABLES.................................................... 107
Strong CYP3A4 inhibitors ............................................................................... 107 10.8.1
Restricted PDE inhibitors ................................................................................ 108 10.8.2
10.9 PRIOR CALCULATION................................................................................. 110
11. DESCRIPTION OF GLOBAL AMENDMENT(S) ....................................... 114
11.1 GLOBAL AMENDMENT 1 ............................................................................ 114
11.2 GLOBAL AMENDMENT 2 ............................................................................ 114
11.3 GLOBAL AMENDMENT 3 ............................................................................ 116

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 11 of 118
Proprietary confidential information © [ADDRESS_1154851]-03 (18.0) / Saved on: [ADDRESS_1154852] Aspartate Aminotransferase
AUC Area under the Curve
b.i.d. bis in die (twice daily dosing)
BI Boehringer Ingelheim
BMI Body Mass Index
CA Competent Authority
Cmax Maximum Concentration
CKD-EPI [INVESTIGATOR_832034]
C-SSRS Columbia-Suicide Severity Rating Scale
CTP Clinical Trial Protocol
CYP Cytochrome P450
DILI Drug Induced Liver Injury
DLCO Diffusion capacity of the lung for carbon monoxide
DMC Data Monitoring Committee
DNA DesoxyriboNucleic Acid
EC Ethics Committee
ECG Electrocardiogram
eCRF Electronic Case Report Form
eDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
EoT End of Treatment
EoTrial End of TrialESR Erythrocyte Sedimentation Rate
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 12 of 118
Proprietary confidential information © [ADDRESS_1154853]-03 (18.0) / Saved on: [ADDRESS_1154854] High Resolution Computed Tomography ScanHV Healthy Volunteers
IB Investigator’s Brochure
IC50 half maximal Inhibitory Concentration
ICH International Council on Harmonisation
IEC Independent Ethics Committee
ILD Interstitial Lung Disease
IMP Investigational Medicinal Product
iPD Important Protocol Deviation
IPF Idiopathic Pulmonary Fibrosis
IRB Institutional Review Board
IRT Interactive Response Technology
ISF Investigator Site File
IUD Intrauterine Device
IUS Intrauterine Hormone-Releasing System
LPLT Last Patient Last Treatment
MedDRA Medical Dictionary for Drug Regulatory Activities
MMRM Mixed effect Model Repeat Measurement
MRD Multiple Rising Dose
mRNA Messenger RiboNucleic Acid

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 13 of 118
Proprietary confidential information © [ADDRESS_1154855]-03 (18.0) / Saved on: 10 Jul 2019OPU Operative Unit
PDE Phosphodiesterase
PI/I
C Patient Information/Informed Consent
PoC Proof of Concept
PPS Per Protocol Set
RA Regulatory Authority
REP Residual Effect Period
RMP Risk Management Program
RNA RiboNucleic Acid
RS Randomised Set
SAE Serious Adverse Event
SmPC Summary of Product Characteristics
SoC Standard of Care
SOP Standard Operating Procedure
SRD Single Rising Dose
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactionst
max Timepoint of Maximum Plasma Concentration
TEAE Treatment Emergent Adverse EventsTK Toxicokinetic
TNF Tumor Necrosis Factor
TS Treated Set
TSAP Trial Statististical Analysis Plan
ULN Upper Level of Normal
UIP usual interstitial pneumonia
WHO World Health Organisation
WOCBP Woman of childbearing potential

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 14 of 118
Proprietary confidential information © [ADDRESS_1154856]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. INTRODUCTION
BI 1015550 is a selective inhibitor of the Phosphodiesterase 4 B (PDE4 B) with broad anti-inflammatory and anti-fibrotic activities. It is under development for the treatment of idiopathic pulmonary fibrosis (IPF).
1.1 MEDICAL BACKGROUND
IPF is a progressive, fibrosing interstitial lung disease (ILD) characterized by [CONTACT_832060] [ R18-2794]. IPF carries a poor prognosis, with a median 
post-diagnosis survival in untreated patients of approximately 3 years [ R18-1413].
IPF occurs worldwide. The prevalence of the disease appears to be increasing, although it is unclear whether this reflects increased recognition or a true increase in incidence. The incidence of IPF appears to be higher in North America and Europe (3 to 9 cases per 100,000 person-years) than in South America and East Asia (fewer than 4 cases per 100,000 person-years) [ R17-4284]. In the [LOCATION_002], the prevalence of IPF has been reported to range 
from 10 to 60 cases per 100,000 [R16-1737], [ R18-0408 ], [R14-2284 ]. Increasing rates of 
hospi[INVESTIGATOR_832035] [ R17-
4284], [ R14-4266], [ P13-[ZIP_CODE] ].
Nintedanib and pi[INVESTIGATOR_832036]/ERS/JRS/ALAT Clinical Practice Guideline for the Treatment of Idiopathic Pulmonary Fibrosis [ R18-2794 ]. Despi[INVESTIGATOR_832037], the medical need remains high in this devastating disease.
 
 
 
 
 
 
 
 
 
 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 15 of 118
Proprietary confidential information © [ADDRESS_1154857]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 16 of 118
Proprietary confidential information © [ADDRESS_1154858]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 17 of 118
Proprietary confidential information © [ADDRESS_1154859]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 18 of 118
Proprietary confidential information © [ADDRESS_1154860]-03 (18.0) / Saved on: [ADDRESS_1154861] time in the BI 1015550 clinical programme.
BI 1015550 will be evaluated as a stand-alone in patients on no background antifibrotic 
treatment and in addition to antifibrotic treatments, i.e. this trial will include patients with or without approved and available antifibrotic treatment (nintedanib or pi[INVESTIGATOR_7735]) at baselineand during the study. 
As per the 1305-0012 Phase Ic study, the 12 weeks treatment duration is being adequately 
supported by [CONTACT_941] 13 weeks toxicology data.
Overall, the Proof of Concept (PoC) of this trial is primarily based on the efficacy results of 
the treatment group not on antifibrotics. PoC and safety of the overall study population of this trial will be used to inform the phase III program.
New treatments are needed that further reduce the decline in FVC, positively affect 
symptoms and improve quality of life in patients with IPF.
Overall, due to the in vitro/in vivo activity of BI 1015550 both in anti inflammatory and anti-
fibrotic assays/models, BI1015550 is hypothesized to have complementary activity (on myofibroblast transformation) to current antifibrotic therapi[INVESTIGATOR_832038] a synergistic effect 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 19 of 118
Proprietary confidential information © [ADDRESS_1154862]-03 (18.0) / Saved on: [ADDRESS_1154863] proliferation if BI 1015550 is shown to be safe and well tolerated when combined with approved antifibrotics.Please refer to section 1.4.1 for further details.
In order to be able to address future scientific questions, patients will be asked to voluntarily  
donate biospecimens for banking (please see ). If the patient agrees, banked section 5.5
samples may be used for future biomarker research and drug development projects, e.g. to 
identify patients that are more likely to benefit from a treatment or experience an adverse event (AE), or to gain a mechanistic or genetic understanding of drug effects and thereby [CONTACT_195883][INVESTIGATOR_014].
1.[ADDRESS_1154864] and the 
effects may be complementary and/or synergistic to those of nintedanib. Based on this, it is postulated that BI 1015550 may provide therapeutic benefit to patients with IPF or other progressive fibrosing ILDs but this has not yet been determined clinically [ c02094779 ].
Due to the limited short treatment duration in this study, only patients on no background antifibrotic treatment may have an improvement of FVC versus baseline. Nevertheless, patients’ participation in this [ADDRESS_1154865] on FVC decline in the overall IPF population.
Two PDE4 inhibitors are marketed with indications of psoriasis and chronic obstructive 
pulmonary disease (COPD). Studies conducted in non-human primates with both marketed compounds suggest that primates are less sensitive than rats to PDE4i-associated toxicity. No adverse vascular changes in humans have been reported.
Overall, BI 1015550 is expected to be safe and well tolerated with an improved tolerability 
compared to other marketed PDE4 inhibitors due to lower affinity for PDE4 D.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 20 of 118
Proprietary confidential information © [ADDRESS_1154866]-03 (18.0) / Saved on: 10 Jul 2019Risks 1.4.2
Table 1.4.2: [ADDRESS_1154867] BI 1015550
Pharmacokinetic 
interaction with strong 
CYP3A4 inhibitors CYP450 3A4 is regarded as the major 
enzyme responsible for BI 1015550 
metabolism in human hepatocytes. 
CYP3A is predicted to contribute to 
~70% of the hepatic metabolism of 
BI 1015550.
In a drug drug interaction trial, the 
strong CYP 3A4 inhibitor 
(itraconazole) increased the exposure 
to BI 1015550 by 1.3-fold (Cmax) 
and 2.2-fold AUC. Potent CYP3A inhibitors are restricted medication.
Safety in addition of marketed antifibrotic 
treatmentsAt the start of this [ADDRESS_1154868] to assess the entire safety data 
on an ongoing basis.
Vasculitis Vasculopathy is an established 
toxicity of PDE4 inhibitors in rats. 
Vasculitis has been shown in both the 
rats and minipi[INVESTIGATOR_832039] 1015550 and it 
has been the basis of the NOAEL (No 
Observable Adverse Effect Level) definition. 
Vasculitis is listed as an important 
potential risk in the RMP for the 
marketed PDE4- inhibitors apremilast 
and roflumilast. 
In marketed PDE4 inhibitors, 
vasculitis has not been identified as 
an adverse drug reaction in humans.Baseline condition or medical history of vasculitis is an exclusion criterion. 
Patient’s withdrawal  in case 
of any vasculitis adverse 
event considered drug related or not.
Increased awareness and 
expedite reporting (AESI).
Gastrointestinal
disorders (e.g.
diarrhoea, nausea,
vomiting, abdominal
pain)Vomiting and diarrhea are important 
dose-limiting side effects of marketed 
oral PDE-[ADDRESS_1154869] to be followed.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 21 of 118
Proprietary confidential information © [ADDRESS_1154870]-03 (18.0) / Saved on: 10 Jul 2019Table 1.4.2: 1 Overview over trial related risks (cont’d)
Possible or known risks
of clinical relevance for 
this trialSummary of data, rationale for the 
riskMitigation strategy
Treatment 
interruption/discontinuation 
is left at the investigator’s 
discretion.
Reproductive toxicity Specific studies to evaluate the 
potential for BI [ADDRESS_1154871] not yet been conducted.Women of childbearing potential are excluded from 
the trial.
Contraception requirements 
for men able to father a 
child.
Weight decrease in 
underweight patients 
(BMI < 18.5 kg/m2)For the marketed PDE4-inhibitors 
apremilast and roflumilast weight loss 
in underweighted patients is 
identified as an important risk.Body weight evaluated at each visit.
Patients who have a BMI 
<18.5 kg/m2 at visit 2, and 
subsequently experience 
unexplained and clinically 
significant weight loss 
(>10%) will be discontinued 
from trial treatment.
Suicidality Two of the currently marketed PDE4 
inhibitors are associated with 
increased risk of depression with some patients reporting suicidal 
ideation and attempts and also 
reported cases of completed suicide.Any suicidal behaviour in 
the past 2 years and any 
suicidal ideation of type 4 or 5 on the Columbia-Suicide 
Severity Ranking Score (C-
SSRS) in the past 3 months 
or at Visit 1 are exclusion 
criteria.
Prospective suicidality 
monitoring, will be 
performed throughout this
trial using the C-SSRS.
Patient’s withdrawal criteria 
in case of suicidal 
behaviouror any suicidal 
ideation of type 4 or 5 in the 
C-SSRS.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 22 of 118
Proprietary confidential information © [ADDRESS_1154872]-03 (18.0) / Saved on: 10 Jul 2019Table 1.4.2: 1 Overview over trial related risks (cont’d)
Possible or known risks 
of clinical relevance for 
this trialSummary of data, rationale for the 
riskMitigation strategy
Drug-induced liver 
injury (DILI)Rare but severe event, standard topic of interest for products in 
development thus under constant 
surveillance by [CONTACT_405735].Timely detection, evaluation, 
and follow-up of laboratory 
alterations in selected liver 
laboratory parameters to 
ensure patients´ safety.
Increased awareness and 
expedite reporting  (AESI).
Trial procedures
Blood Sampling As with all blood sampling, there is a 
risk of mild pain, local irritation, or bruising (a black or blue mark) at the 
puncture site. Furthermore, there is a 
small risk of light-headedness and/or 
fainting. In rare cases, the puncture 
site can also become infected or 
nerves may be damaged, inducing long-lasting abnormal sensations 
(paresthesia), impaired sensation of 
touch and persistent pain.These risks will be addressed by [CONTACT_832061]
-close clinical monitoring 
for AEs;
-selection of experienced sites and site staff.
HRCT The more radiation is received over 
the course of a life, the greater risk of 
having cancerous tumors or of 
inducing changes in genes. The changes in genes possibly could 
cause abnormalities or disease in 
future offspring. The radiation in this 
trial is not expected to greatly 
increase these risks, but the exact increase in such risks is not known.HRCT only required in case no historical one (less than 
12 months) is available or in 
case of insufficient quality.
These risks will be addressed 
by [CONTACT_832061]
-close clinical monitoring 
for AEs;
-selection of experienced 
sites and site staff.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 23 of 118
Proprietary confidential information © [ADDRESS_1154873]-03 (18.0) / Saved on: 10 Jul 2019Table 1.4.2: 1 Overview over trial related risks (cont’d)
Possible or known risks 
of clinical relevance for 
this trialSummary of data, rationale for the 
riskMitigation strategy
Lung function 
measurements 
(Spi[INVESTIGATOR_023])Risks and discomforts associated 
with lung function testing may 
include shortness of breath, dizziness, 
or headache during the breathing 
tests.These risks will be addressed 
by [CONTACT_832062] 
-close clinical monitoring 
for AEs;
-selection of experienced 
sites and site staff;
-training from vendor to 
conduct correct 
manoeuvre.
Other risks
Administration of 
PlaceboIf the patient is randomised to receive a placebo, the patient´s condition 
could get worse during the course of 
the trial.The placebo treatment until Week 12 is deemed 
acceptable from an ethical 
perspective.
SARS CoV-2 infection Based on the pharmacological 
mechanism and existing non-clinical and clinical data there is no indication that treatment with BI 1015550 may increase the risk of severe clinical courses of SARS-COV-2 infection. 
However, patients with IPF may 
be at risk of severe clinical courses due to the underlying chronic progressing lung fibrosis, associated co-morbidities and potential use of immunosuppressive co-medications.Even though an increased risk of SARS-CoV-2 infection – or of a more severe COVID-19 diseasein case of such an infection appears unlikely,patients with active or recent SARS CoV-2 infection will not be included in the trial (see section 3.3.3 ). In addition, 
during the course of the trial, treatment with BI 1015550 will be discontinued in case of a confirmed SARS-CoV-2 infection (refer to section 
[IP_ADDRESS])
Discussion 1.4.3
Treatment with BI 1015550 has the potential to provide significant benefit to patients with
IPF by [CONTACT_832063], improving burdensome symptoms and 
quality of life over a long term period.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 24 of 118
Proprietary confidential information © [ADDRESS_1154874]-03 (18.0) / Saved on: 10 Jul 2019The purpose of this 12 week Phase II trial is to investigate the efficacy and safety of BI 1015550 and provide  proof of concept of clinical activity for further progression to Phase III.
The available results of completed Phase I and Phase I C trials in HVs and IPF patients 
respectively,show a favorable safety profile  at single doses tested up to 48 mg in HVs and at up to 18 mg b.i.d in multiple doses tested for up to 12 weeks in IPF patients.
In this trial, the dose of 18 mg b.i.d. administered orally for 12 weeks is considered 
appropriate from both a preclinical (i.e supported by [CONTACT_941] 13 weeks toxicology data) and clinical point of view, consequent to the benign safety profile to date.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 25 of 118
Proprietary confidential information © [ADDRESS_1154875]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. TRIAL OBJECTIVES AND ENDPOINTS
2.1 MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
Main objectives 2.1.1
- To investigate the efficacy of BI 1015550 compared to placebo based on the change 
from baseline in Forced Vital Capacity (FVC).
- To investigate safety and tolerability of BI 1015550 in the overall trial population.  
Primary endpoints 2.1.2
The primary endpoint is the change from baseline in FVC at 12 weeks (in mL).
Secondary endpoint 2.1.3
The percentage N (%) of patients with Treatment Emergent Adverse Events (TEAE).

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 26 of 118
Proprietary confidential information © [ADDRESS_1154876]-03 (18.0) / Saved on: [ADDRESS_1154877] to evaluate the safety and tolerability of BI 1015550:
∀Change in C-SSRS (Columbia Suicidal Severity Rating Scale) over time.
∀Change from baseline in weight over time.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 27 of 118
Proprietary confidential information © [ADDRESS_1154878]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. DESCRIPTION OF DESIGN AND TRIAL POPULATION
3.1 OVERALL TRIAL DESIGN 
This phase II trial is a double-blind, placebo-controlled comparison of BI 1015550 18 mg 
b.i.d over 12 weeks in patients treated with antifibrotic treatment or not treated with
antifibrotic treatment at baseline.
Patients randomised into the trial will be treated for 12 weeks. The patients will be included 
in the trial and during the screening period (up to 44 days), the eligibility criteria will be assessed. After this period, the eligible patients will be randomised in the trial in a 2:1 ratio (BI 1015550 18 mg b.i.d/ placebo b.i.d).Patients will be proposed an optional substudy (restricted to some sites/countries). To participate, patient will be proposed to sign a dedicated informed consent. More details about this substudy can be found in section 5.6.
After the patients have terminated their treatment period, they will enter a 1-week follow-up period. Follow up visit will be the End of Trial.In case of early treatment discontinuation, the patient is expected to follow the trial schedule as per protocol.
Figure 3.1:[ADDRESS_1154879] in situations where effective 
therapi[INVESTIGATOR_832040] a placebo-controlled trial could be considered not to be ethical, 
there is currently no approved pharmacotherapy that can finally stop the FVC decline and the ScreeningFollow
Up
6
12 02
44
23
85Placebo (approx. 50 pat)BI 1015550 18 mg bid (approx.100 pat)
WeekVisit 1Randomised 2:1
7
13
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 28 of 118
Proprietary confidential information © [ADDRESS_1154880]-03 (18.0) / Saved on: [ADDRESS_1154881] debilitating symptoms in these patients.
A total minimum of 60 patients per group (with or without antifibrotic treatment) are 
included in this study with up to 150 patients in total with an unequal allocation ratio (1:2) selected for the placebo and the BI 1015550 treatment group. The usage of an unequal allocation ratio is explained by [CONTACT_832064] (via Bayesian borrowing). This approach leads to a better precision, while reducing the number of required patients on placebo at the same time and increasing the number of patients treated on BI [ADDRESS_1154882] 60 patients on antifibrotic background treatment and 60 patients not on antifibrotic treatment will be included in the trial. If necessary, recruitment of one group will be stopped in order to achieve this. The randomisation of patients will be stratified according their antifibrotic treatment background status at baseline.
Only male patients and postmenopausal or surgically sterilised female patients will be 
included into the study because hitherto no data on reproductive toxicology are available.
Screening of patients for this trial is competitive, i.e. screening for the trial will stop at all 
sites at the same time once a sufficient number of patients has been screened. Investigators 
will be notified about screening completion and will then not be allowed to screen additional 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 29 of 118
Proprietary confidential information © [ADDRESS_1154883]-03 (18.0) / Saved on: 10 Jul 2019patients for this trial. Patients in screening at this time will be allowed to continue to randomisation if eligible.
A log of all patients enrolled into the trial (i.e. who have signed informed consent) will be 
maintained in the Investigator Site File (ISF) irrespective of whether they have been treated with investigational drug or not.
Patients who do not meet all inclusion criteria or meet one or more exclusion criteria should
not be randomized into the trial.If a patient was randomized in error (did not meet all inclusion criteria or met one or moreexclusion criteria on the day of randomization), the sponsor should be contact[CONTACT_832065] a decision on treatment discontinuation or continuous trial participation based onindividual benefit-risk assessment.
Main diagnosis for trial entry
3.3.1
Patients diagnosed with IPF and who comply with eligibility requirements may qualify for participation in the trial.
Please refer to section 8.3.1 (Source Documents) for the documentation requirements 
pertaining to the in- and exclusion criteria.
Inclusion criteria 3.3.2
1. Patients aged ≥40 years when signing the informed consent.
2. Diagnosis : for detailed specifications see also Appendix 10.5 )
a. IPF based on 2018 ATS/ERS/JRS/ALAT Guideline [ R18-2794 ] as confirmed 
by [CONTACT_832066] [ADDRESS_1154884] pattern consistent with the clinical diagnosis of 
IPF, as confirmed by [CONTACT_832067] 2*
*if indeterminate HRCT finding IPF may be confirmed locally by (historical) biopsy
3. Stable for at least [ADDRESS_1154885] to be either :
∀not on therapy with nintedanib or pi[INVESTIGATOR_16352] 8 weeks prior to Visit 
1 (combination of nintedanib plus pi[INVESTIGATOR_832041]), or
∀on stable* therapy with nintedanib or pi[INVESTIGATOR_16352] 8 weeks prior to 
Visit 1 and planning to stay stable on this background therapy after 
randomisation.
[*stable therapy is defined as the individually and general tolerated regimen of either pi[INVESTIGATOR_39568]]
4. Forced Vital Capacity (FVC) ≥45% of predicted normal at Visit 1
5. DLCO (corrected for haemoglobin [Hb] [Visit 1]) ≥ 25% to < 80% of predicted 
normal at Visit 1.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 30 of 118
Proprietary confidential information © [ADDRESS_1154886]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. Signed and dated written informed consent in accordance with ICH-GCP and local 
legislation prior to admission to the trial.
Exclusion criteria 3.3.3
1. Relevant airways obstruction (pre-bronchodilator FEV1/FVC < 0.7) at Visit 1.2. In the opi[INVESTIGATOR_689], other clinically significant pulmonary abnormalities.3. Acute IPF exacerbation within 4 months prior to screening and/or during the screening 
period (investigator-determined).
4. Lower respi[INVESTIGATOR_832032] 4 weeks prior to Visit 1  
and/or during the screening period.
5. Major surgery (major according to the investigator’s assessment) performed within 3 
months prior to Visit 1 or planned during the course of the trial. (Being on a transplant list is allowed).
6. Any documented active or suspected malignancy or history of malignancy within 5 years 
prior to Visit 1, except appropriately treated basal cell carcinoma of the skin, “under surveillance” prostate cancer or in situ carcinoma of uterine cervix.
7. Evidence of active infection (chronic or acute) based on clinical exam or laboratory 
findings (see table 5.2.3 :1 ) at Visit [ADDRESS_1154887] 2 years (i.e. actual attempt, interrupted attempt, 
aborted attempt, or preparatory acts or behavior).
9. Any suicidal ideation of type [ADDRESS_1154888] 3 months or at Visit 1 (i.e. 
active suicidal thought with method and intent but without specific plan; or active suicidal thought with method, intent and plan).
10. Baseline condition or medical history of vasculitis.11. AST or ALT > 1.[ADDRESS_1154889] or total Bilirubin > 1.[ADDRESS_1154890] at Visit 1.12. eGFR (Chronic Kidney Disease Epi[INVESTIGATOR_10444] [CKD-EPI] formula or 
Japanese version of CKD-EPI [INVESTIGATOR_832042]) ≤45 ml/min/1.73 m2 at Visit 1.
[Note: Laboratory parameters from Visit [ADDRESS_1154891] to satisfy the laboratory threshold values as shown above. Visit 
2 laboratory results will be available only after randomisation. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 
1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result 
of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved].
13. Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment).
14. Cardiovascular diseases, any of the following:
a. Severe hypertension (uncontrolled under treatment ≥160/100 mmHg at multiple 
occasions) within 3 months of Visit 1b. Myocardial infarction within 6 months of Visit 1c. Unstable cardiac angina within 6 months of Visit 1
15. History of thrombotic event (including stroke and transient ischemic attack) within [ADDRESS_1154892]  (except 
appendectomy or simple hernia repair).
17. Patients who must or wish to continue the intake of restricted medications (see section 
[IP_ADDRESS] and appendix 10.8 ) eg. strong CYP3A4 inhibitor, prednisone >15mg/day or any 
drug considered likely to interfere with the safe conduct of the trial

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 31 of 118
Proprietary confidential information © [ADDRESS_1154893]-03 (18.0) / Saved on: 10 Jul 201918. Patients not expected to comply with the protocol requirements or not expected to 
complete the trial as scheduled.
19. Previous randomisation in this trial.20. Currently enrolled in another investigational device or drug trial, or less than 30 days 
since ending another investigational device or drug trial(s), or receiving other investigational treatment(s).
21. In the opi[INVESTIGATOR_689], active alcohol or drug abuse.22. Inability to refrain from smoking on trial days.
23. Male patients who do not agree to minimize the risk of female partners becoming
pregnant from first dosing day until 3 months after the study completion. Acceptable 
methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive used for at least two months prior), true sexual abstinence (when this is in line with the preferred and usual lifestyle of the patient), or surgically sterilized, including vasectomy.
24. Women who are not surgically sterilised or who are not postmenopausal, defined as at 
least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of Follicle-stimulating hormone (FSH) above 40 U/L and estradiolbelow 30 ng/L is confirmatory).
25. History of allergy or hypersensitivity or contraindications to the class of drugs under 
study including known hypersensitivity to the drug or its excipi[INVESTIGATOR_840].
26. Patients with a significant disease or condition other than IPF which in the opi[INVESTIGATOR_832043], may put the patient at risk because of participation, interfere with study procedures, or cause concern regarding the patient’s ability to participate in the study or any medical condition which could lead to a life expectancy <12months
27. The patient has a confirmed  infection with SARS-CoV-2 within the 4 weeks prior to Visit 1 
and/or during the screening period.  
Withdrawal of patients from treatment or assessments 3.3.4
Patients may discontinue trial treatment or withdraw consent to trial participation as a whole(“withdrawal of consent”) with very different implications; please see sections [IP_ADDRESS] and 
[IP_ADDRESS] below.
Every effort should be made to keep the patients in the trial: if possible on treatment, or at least to collect important trial data.Measures to control the withdrawal rate include careful patient selection, appropriate explanation of the trial requirements and procedures prior to trial enrolment, as well as theexplanation of the consequences of withdrawal. The decision to discontinue trial treatment or withdraw consent to trial participation and the reason must be documented in the patient files and CRF. If applicable, consider the requirements for Adverse Event collection reporting (please see sections [IP_ADDRESS].1 and 
[IP_ADDRESS].2).
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 32 of 118
Proprietary confidential information © [ADDRESS_1154894]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].3.4.1 Discontinuation of trial treatment
An individual patient will discontinue trial treatment if:
∀The patient wants to discontinue trial treatment, without the need to justify the decision.
∀The patient has repeatedly shown to be non-compliant with important trial procedures 
and, in the opi[INVESTIGATOR_15566], the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements in the future.
∀The patient experiences unacceptable adverse events in the opi[INVESTIGATOR_871].
∀The patient fulfills the AESI definition of hepatic injury (see section [IP_ADDRESS].6 ).
∀The patient experiences an infection with SARS-CoV-2. 
∀The patient needs to take concomitant medication that interferes with the investigational 
medicinal product or other trial treatment (see section 4.2.2).
∀The patient can no longer receive trial treatment for medical reasons (such as surgery, 
adverse events, other diseases, or pregnancy). The patient exhibits serious suicidality, in 
the clinical judgment of the investigator or according to the following criteria:
- any suicidal behavior (i.e. actual attempt, interrupted attempt, aborted attempt,
or preparatory acts or behaviour)- any suicidal ideation of type 4 or 5 in the C-SSRS (i.e. active suicidal thoughtwith intent but without specific plan, or active suicidal thought with plan and intent)
∀The patient shows any vasculitis adverse event considered drug related or not.
∀For patients with a BMI<18,5 kg/m
2at Visit 2 only : unexplained and clinically 
significant (>10%) weight loss. 
∀The patient shows clinically relevant changes in ECG requiring intervention.
∀The patient shows a QTc>500 ms in ECG.
In case of a temporary reason, trial treatment should be restarted if medically justified, please see section 4.1.4 .
If new efficacy/safety information becomes available, Boehringer Ingelheim will review thebenefit-risk-assessment and, if needed, pause or discontinue the trial treatment for all patients or take any other appropriate action to guarantee the safety of the trial patients. If the trial treatment is discontinued, the patients remain in the trial if possible and should still follow the trial schedule as outlined in the Flow Chart and section 6.2.[ADDRESS_1154895] drug intake.
[IP_ADDRESS] Withdrawal of consent to trial participation
Patients may withdraw their consent to trial participation at any time without the need to 
justify the decision.If a patient wants to withdraw consent, the investigator should be involved in the discussion with the patient and explain the difference between trial treatment discontinuation and withdrawal of consent to trial participation, as well as explain the options for continued follow-up after trial treatment discontinuation, please see section [IP_ADDRESS] above.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 33 of 118
Proprietary confidential information © [ADDRESS_1154896]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].3.4.3 Discontinuation of the trial by [CONTACT_35949] a particular trial
site at any time for the following reasons:1. Failure to meet expected enrolment goals overall or at a particular trial site.2. New efficacy or safety information invalidating the earlier positive benefit-risk-
assessment, please see section [IP_ADDRESS] .
3. Deviations from GCP, the trial protocol, or the contract impairing the appropriate conduct 
of the trial.
Further follow up of patients affected will occur as described in section [IP_ADDRESS].The investigator / the trial site will be reimbursed for reasonable expenses incurred in case of trial termination (except in case of the third reason).
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 34 of 118
Proprietary confidential information © [ADDRESS_1154897]-03 (18.0) / Saved on: [ADDRESS_1154898] has been manufactured by [CONTACT_35950] & Co. KG or a 
qualified vendor (placebo).
Identity of the Investigational Medicinal Products 4.1.[ADDRESS_1154899] are given below:
Table 4.1.1:1 BI 1015550 6 mg
Substance:BI 1015550
Pharmaceutical formulation:film-coated tablets
Source:BI Pharma GmbH & Co. KG, [LOCATION_013]
Unit strength:6 mg 
Posology:b.i.d
Mode of administration:Oral
Table 4.1.1:2 Placebo matching BI 1015550 6 mg
Substance:Placebo matching in size, weight, colour and shape 
to 6 mg tablet of BI 1015550
Pharmaceutical formulation:film-coated tablets
Source:BI Pharma GmbH & Co. KG, [LOCATION_013]
Unit strength:n.a
Posology:b.i.d
Method and route of administration:Oral
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 35 of 118
Proprietary confidential information © [ADDRESS_1154900]-03 (18.0) / Saved on: 10 Jul 2019Table 4.1.1: 3 BI 1015550 12 mg
Substance:BI 1015550
Pharmaceutical formulation:film-coated tablets
Source:BI Pharma GmbH & Co. KG, [LOCATION_013]
Unit strength:12 mg
Posology:b.i.d
Method and route of administration:Oral
Table 4.1.1: 4 Placebo matching BI 1015550 12 mg
Substance:Placebo matching in size, weight, colour and shape to 12mg tablet of BI 1015550
Pharmaceutical formulation:film-coated tablets
Source:BI Pharma GmbH & Co. KG, [LOCATION_013]
Unit strength:n.a
Posology:b.i.d
Method and route of administration:Oral
Selection of doses in the trial and dose modifications 4.1.[ADDRESS_1154901] transition experiments.These experiments showed IC50‘s of 210 – 250 nM for mono and 23–110 nM for synergistic action with nintedanib. Also, the clinical total coverage (at steady state) is equal or above the fibroblast IC50‘s, using doses equal or above 12 mg b.i.d (actual and modelled data, assuming that total concentrations of BI [ADDRESS_1154902]).
This assumption is supported by [CONTACT_832068] (LPS 
(Lipopolyssacharide)-stimulated TNF(tumor Necrosis factor)- α and IFN (interferon)-γ
release), which may not be directly linked to an anti-fibrotic action, but can be linked to an 
anti-inflammatory action on macrophages and T cells in IPF. A substantial and significant 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 36 of 118
Proprietary confidential information © [ADDRESS_1154903]-03 (18.0) / Saved on: [ADDRESS_1154904] target engagement was shown in 1305-0011 phase I trial using 12 mg b.i.d dose and 36 mg and 48 mg single doses.Nintedanib, pi[INVESTIGATOR_832044] 1015550 are effective in animal models of bleomycin induced lung fibrosis. Comparison of efficacious exposure levels in animals for the two marketed anti-fibrotics with the reached clinical exposure indicates an approx. 5-fold higher necessary exposure in the animal bleomycin studies.
Assuming that this 5-fold pre-clinical over-prediction is also relevant for BI 1015550 this 
leads to a predicted human efficacious dose of BI 1015550 in IPF of 12–15 mg b.i.d.
Taking together, therefore the maximum dose of 18 mg b.i.d is expected to be a therapeutic 
dose. This dose was tested in trial 1305-0012 in 15 IPF patients not on background antifibrotic treatment, administered for 4 to 12 weeks which was supported by [CONTACT_941] 13 weeks rat and minipig toxicology data.
In 1305-0012 trial, the preliminary results show geometric mean C
max,ss and AUC τ,ssvalues of 
460 nM and 3720 nM ∙h reached respectively for BI 1015550 within the 18 mg dose group 
with good safety and tolerability of BI 1015550 18 mg b.i.d. in 15 IPF patients not on 
background antifibrotic treatment.
In this Phase II trial (1305-0013), the exposure in IPF patients at the planned dose of 18 mg 
b.i.d is expected: 
a) to fall within range of the estimated therapeutic range and b) to be below the pre-defined maximal acceptable human systemic exposure limit as defined in trial 1305-0012 on the basis of the 13 weeks rat toxicology data.
In addition, based on the current knowledge on BI 1015550 preclinical evaluation no significant DDI interactions neither between BI 1015550 and nintedanib, nor between BI 1015550 and pi[INVESTIGATOR_832045].
Method of assigning patients to treatment groups
4.1.3
After the assessment of all in- and exclusion criteria by [CONTACT_1755]/or his/her staff, each eligible patient will be randomised to treatment groups according to a randomisationplan in a 2:1 ratio at Visit 2 via Interactive Response Technology (IRT). Note that the medication number is different from the patient number.
The randomisation will be stratified according the background status of the patient (either 
treated or not treated with antifibrotic treatment).
Each patient fulfilling all in- and exclusion criteria will be randomised via IRT at Visit 2 to 
one of the 2 following arms in a 2:1 ratio:
∀BI 1015550 18 mg b.i.d
∀Placebo b.i.d
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 37 of 118
Proprietary confidential information © [ADDRESS_1154905]-03 (18.0) / Saved on: 10 Jul 2019Drug assignment and administration of doses for each patient 4.1.4
The patient will be treated starting at Visit 2 for 12 weeks (until Visit 6).
Table 4.1.4: 1 Dosage and treatment schedule
Treatment arm BI 1015550
6 mg tabletPlacebo matching 6 
mg tabletBI 1015550
12 mg tabletPlacebo matching 
12 mg tablet
To be taken twice daily, in the morning and in the evening
18 mg 1 1
Placebo 1 1
Based on the treatment allocated at randomisation, the IRT system will be used to dispense 
the appropriate medication kits at each visit.
Medication is packaged in wallet containing 4 times 4 blisters stripes of 7 tablets each, each
containing 28 film-coated tablets so 112 films-coated tablets per wallet to cover 4 weeks treatment. To ensure patients receive adequate supply of study medication, kits will be dispensed at clinic visits in quantities as outlined in table 4.1.4: 2
Table 4.1.4: 2 Number of IMP kits dispensed at each visit
Study Visits 2 3 4 5
Number of 
IMP kits dispensed1+1* 1 1
*: the second kit dispensed at Visit 2 is a reserve kit to cover the time windows at each visit. It will be 
brought back at each visit by [CONTACT_832069]. When less than 7 tablets left in the kit or when expi[INVESTIGATOR_832046], the site 
should perform an additional IRT call to allocate a new kit as reserve.
The patients should swallow the trial medication (“sun” column for the morning, “moon” 
column for the evening intake) together with a glass of water (~250 mL), and should observe a dose interval of 12 hours. Effort should be made to ensure that drug administration occursat the same time every day +/- 30 min (between 06:00 and 11:00 in the morning, and between 18:00 and 23:00 in the evening).
A forgotten dose should be skipped if the time window to the next dose is less than [ADDRESS_1154906] should only be dispensed to participating patients according to 
the protocol by [CONTACT_832070].
During the COVID-19 pandemic, physical visits to the sites may need to be restricted to 
ensure patient safety. Based on a thorough assessment of the benefits and risks, the 
investigator may still decide to continue the trial treatment and trial medication may be 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 38 of 118
Proprietary confidential information © [ADDRESS_1154907]-03 (18.0) / Saved on: 10 Jul 2019shipped to the patient’s home if acceptable according to local law and regulations (for more details see section 6.2.2 ).
Blinding and procedures for unblinding 4.1.5
[IP_ADDRESS] Blinding
Patients, investigators, central reviewers, and everyone involved in trial conduct or analysis
(except bioanalytics and possibly DMC members) or with any other interest in this double-blind trial will remain blinded with regard to the randomised treatment assignments until after database lock.
The access to the randomisation code will be kept restricted until its release for analysis.
The randomisation codes will be provided to bioanalytics to allow samples from placebo patients to be excluded from the analyses of pharmacokinetic (PK) samples. Bioanalytics will not disclose the randomisation code, which patients have been tested or the results of their measurements until the trial is officially unblinded.
[IP_ADDRESS] Unblinding and breaking the code
Emergency unblinding will be available to the investigator via IRT. It must only be used in
an emergency situation when the identity of the trial drug must be known to the investigatorin order to provide appropriate medical treatment or otherwise assure safety of trialparticipants. The reason for unblinding must be documented in the source documents and/or appropriate CRF page.
Due to the requirements to report Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs), it may be necessary for a representative from BI’s Pharmacovigilance group to access the randomisation code for individual patients during trial conduct. The access to the code will only be given to authorised Pharmacovigilance representatives for processing in the PV database system and not be shared further. 
Packaging, labelling, and re-supply
4.1.6
The investigational medicinal products will be provided by [CONTACT_23292] a designated CRO. They will be packaged and labelled in accordance with the principles of Good Manufacturing Practice (GMP).Re-supply to the sites will be managed via an IRT system, which will also monitor expi[INVESTIGATOR_15567].For details of packaging and the description of the label, refer to the ISF.
Storage conditions
4.1.[ADDRESS_1154908] be maintained for documentation.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 39 of 118
Proprietary confidential information © [ADDRESS_1154909]-03 (18.0) / Saved on: 10 Jul 2019If the storage conditions are found to be outside the specified range, the Clinical Research Associate CRA (as provided in the list of contacts) must be contact[CONTACT_15608].
Drug accountability
4.1.8
The investigator or designee will receive the investigational drugs delivered by [CONTACT_832071]:
∀Approval of the clinical trial protocol by [CONTACT_1201] / ethics committee, HA / RA approval.
∀Availability of a signed and dated clinical trial contract between the sponsor and the 
investigational site,
∀Approval/notification of the regulatory authority, e.g. competent authority,
∀Availability of the curriculum vitae of the Principal Investigator,
∀Availability of a signed and dated clinical trial protocol,
∀Availability of the proof of a medical license for the Principal Investigator,
∀Availability of FDA Form 1572 (if applicable).
Investigational drugs are not allowed to be used outside the context of this protocol. They must not be forwarded to other investigators or clinics. Patients should be instructed to return unused investigational drug.The investigator or designee must maintain records of the product’s delivery to the trial site, the inventory at the site, the use by [CONTACT_6904], and the return to the sponsor or warehouse / drug distribution centre or alternative disposal of unused products. If applicable, the sponsor or warehouse / drug distribution centre will maintain records of the disposal. 
These records will include dates, quantities, batch / serial numbers, expi[INVESTIGATOR_4061] (‘use- by’) dates, 
and the unique code numbers assigned to the investigational medicinal product and trialpatients. The investigator or designee will maintain records that document adequately that the patients were provided the doses specified by [CONTACT_15616] (CTP) and reconcile all investigational medicinal products received from the sponsor. At the time of return to the appointed CRO, the investigator or designee must verify that all unused or partially used drug supplies have been returned by [CONTACT_832072]’s possession.
4.2 OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS
Other treatments and emergency procedures
4.2.1
There are no special emergency procedures to be followed.
Temporary treatment interruption for up to one week is allowed to manage adverse events
(such as GI events, need to take restricted medication etc…) will be documented on the respective eCRF page.
A maximum total duration of interruptions of 2 weeks is allowed.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 40 of 118
Proprietary confidential information © [ADDRESS_1154910]-03 (18.0) / Saved on: 10 Jul 2019Restrictions 4.2.2
[IP_ADDRESS] Restrictions regarding concomitant treatment
All concomitant or rescue therapi[INVESTIGATOR_79005] (including time of intake on study days) 
on the appropriate eCRF page.
Marketed antifibrotic treatment (nintedanib or pi[INVESTIGATOR_7735]) is allowed at baseline when 
stabilised according to eligibility criteria and is expected to be stable throughout the trial.
Temporary antifibrotics interruption/dose reduction are left at the discretion of the investi 
gator eg to manage gastrointestinal effects.
Table [IP_ADDRESS]:1 Restricted medication 
MedicationPrior to 
StudyScreening PeriodTreatment periodFollow up period 
Potent CYP3A inhibitorsPermittedNot 
permittedNot permitted Permitted
Nintedanib/Pi[INVESTIGATOR_832047] 1 (refer to inclusion 3)Permitted Permitted Permitted Permitted
Nintedanib/Pi[INVESTIGATOR_832048] 1Not 
permitted
1Not 
permittedNot permitted Permitted
PDE inhibitors2 Not 
permitted2Not 
permittedNot permittedNot 
permitted
Prednisone>15mg/
day or equivalentPermittedNot 
permitted3Not permitted4Permitted
Footnotes to restricted medication Table [IP_ADDRESS]:1
1. Not permitted during the 8 weeks prior to screening visit (Visit 1)
2. This covers non selective PDE inhibitors as well as PDE1, PDE3, PDE4 and PDE10 
inhibitors. Not permitted 30 days prior to randomisation (Visit 2).
3. Not permitted during the 2 weeks prior to randomisation (Visit 2).
4. Prednisone >15mg/day or equivalent can be prescribed during the treatment period in 
case of acute exacerbation as described in section [IP_ADDRESS].5. Table of equivalent doses 
of corticosteroids can be found in Table 10.7: 1
Lists of potent CYP3A inhibitors and PDE inhibitors can be found in Appendix 10.8 .
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 41 of 118
Proprietary confidential information © [ADDRESS_1154911]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].2.2.2 Restrictions on diet and life style
Patients should refrain from consuming Methylxanthine-containing drinks or foods (such as 
coffee, tea, cola, energy drinks, and chocolate) in the 24 h preceding each on site visit.Patients should also refrain drinking grapefruit juice during the course of the trial.
[IP_ADDRESS] Contraception requirementsMen able to father a child must use two medically approved methods of birth control 
throughout the trial, and for a period of at least [ADDRESS_1154912] trial drug intake : one barrier method, and one highly effective non-barrier method.
Men (trial participant or partner of a trial participant) must be vasectomised with documented 
absence of sperm or use a condom if their sexual partner is a WOCBP.WOCBP (partner of a trial participant) must use a highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly if their sexual partner is a man able to father a child.
∀Combined (estrogen and progestogen containing) hormonal birth control that prevents ovulation (oral [approved in Japan], intravaginal [unapproved in Japan], transdermal[unapproved in Japan]).
∀Progestogen-only hormonal birth control that prevents ovulation (oral, injectable, 
implantable) [unapproved in Japan].
∀Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).
∀Bilateral tubal occlusion.
Or:
Patients must abstain from male-female sex. This is defined as being in line with the preferred and usual lifestyle of the patient. Periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods; declaration of abstinence for the duration of exposure to study drug; and withdrawal are not acceptable.
4.3 TREATMENT COMPLIANCE
Patients are requested to bring all remaining trial medication including empty package 
material with them when attending visits.
Based on tablet counts, treatment compliance will be calculated as shown in the formula 
below. Compliance will be verified by [CONTACT_195897].
Treatment compliance (%) =Number of tablets actually taken ∃[ADDRESS_1154913] been taken as 
directed by [CONTACT_35953] 80-120%, site staff will explain to the patient the importance of treatment compliance.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 42 of 118
Proprietary confidential information © [ADDRESS_1154914]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. ASSESSMENTS
5.1 ASSESSMENT OF EFFICACY
FVC 5.1.1
FVC and FEV1 will be assessed using standardised spi[INVESTIGATOR_832049]-calibrated disposable flow sensors. These sensors 
demonstrate variability within the required standards of +/-3% determined by [CONTACT_345262] (ATS)/European Respi[INVESTIGATOR_3764] (ERS) [ P05-[ZIP_CODE] ]. As such there is 
no need to conduct daily calibration prior to use.Efforts should be made, to schedule the spi[INVESTIGATOR_832050] ± 90 min , with reference to baseline measurement (Visit 2). On days of clinic visits, patients must refrain from strenuous activity at least [ADDRESS_1154915], or areas with strong odours (e.g. perfumes). If treated with bronchodilators, wash-out of [ADDRESS_1154916] FVC each obtained on any of three blows meeting the ATS/ERS criteria (with a maximum of eight attempts). Spi[INVESTIGATOR_832051].
DLCO
5.1.[ADDRESS_1154917] will be carried out according to the ATS/ERS guidelines [ R06-2002 ].
Before the test the maneuvers should be demonstrated and the patient carefully instructed. The mean value between at least two acceptable tests should be reported. Please refer to appendix 10.3 for additional information.
For each patient, spi[INVESTIGATOR_832052]. DLCO should always been performed after spi[INVESTIGATOR_038].
 
 
 
 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 43 of 118
Proprietary confidential information © [ADDRESS_1154918]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 44 of 118
Proprietary confidential information © [ADDRESS_1154919]-03 (18.0) / Saved on: [ADDRESS_1154920] be included in the source documents available at the site. 
Vital signs
5.2.2
Vital signs will be evaluated at the time points specified in the Flow C hart, prior to blood 
sampling.This includes systolic and diastolic blood pressure and pulse rate (electronically or by [CONTACT_15620] 1 minute) in a seated position after [ADDRESS_1154921] be included in the source documents available at the site.
Safety laboratory parameters
5.2.3
Safety laboratory parameters to be assessed are listed in Table [IP_ADDRESS] . For the sampling time 
points please see the Flow Chart.
Analyses of most parameters will be performed by a central laboratory, the respective 
reference ranges will be provided in the ISF. ESR will be performed on-site using supplies provided by [CONTACT_2237]. The value for ESR will be reported directly by [CONTACT_17072]. Patients do not have to be fasted for the blood sampling. 
Instructions regarding sample collection, sample handling/ processing and sample shippi[INVESTIGATOR_23228]. The central laboratory will send reports to the investigator. It is the responsibility of the investigator to evaluate the laboratory reports. Clinically relevant abnormal findings as judged by [CONTACT_23305] (please refer to section 5.2.6).
In case the criteria for hepatic injury are fulfilled, a number of additional measures will be performed (please see section [IP_ADDRESS] and the DILI Checklist provided in the eDC system.
The amount of blood taken from the patient concerned will be increased due to this additional 
sampling.
The central laboratory will transfer the results of the analysis to the sponsor.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 45 of 118
Proprietary confidential information © [ADDRESS_1154922]-03 (18.0) / Saved on: 10 Jul 2019Table 5.2.3:[ADDRESS_1154923] name 
[CONTACT_577121] (RBC)Reticulocyte countWhite blood cell count (WBC)
Platelet count
Erythrocyte sedimentation rate (ESR)
Automatic WBC differential 
(relative and absolute)Neutrophils, eosinophils, basophils, monocytes, lymphocytes
Manual differential WBC (if automatic
differential WBC is abnormal)Polymorphnuclear neutrophils (segs), band neutrophils (stabs), eosinophils, basophils, monocytes, lymphocytes 
Coagulation Activated partial thromboplastin time (aPTT)
Prothrombin time (Quick’s test and INR)Fibrinogen
Enzymes Aspartate transaminase (AST/GOT)
Alanine transaminase (ALT/GPT)
Alkaline phosphatase (AP)
Gamma-glutamyl transferase (GGT)
Creatine kinase (CK)
CK-MB, only if CK is elevated 
Lactate dehydrogenase (LDH)Lipase
Amylase
Hormones Thyroid stimulating hormone (TSH)
fT3, fT4
Substrates Plasma glucose
Creatinine Total bilirubin 
Direct and indirect bilirubin
Total protein
High sensitivity C-Reactive Protein (hs CRP)
Brain Natriuretic Peptide (BNP)
Uric acid 
Total cholesterol Triglycerides
Albumin
Electrolytes Sodium
Potassium
Chloride
Calcium
Inorganic phosphate
Urine analysis
(semi-quantitative measurements; -, +, 
++, +++)pHGlucose
Erythrocytes
LeukocytesProtein 
Nitrite 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 46 of 118
Proprietary confidential information © [ADDRESS_1154924]-03 (18.0) / Saved on: 10 Jul 2019eGFR will be analysed and calculated by [CONTACT_832073] (see in the Flow Chart ).
eGFR will be calculated by [CONTACT_657231]-EPI [INVESTIGATOR_14420] (see Section 10.6 ) and using the 
Jaffe assay for serum creatinine measurement, IDMS standardized.
Electrocardiogram Recording 5.2.4
Twelve-lead resting ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a computerised electrocardiograph which will be provided to the sites, at the time points given in the Flow Chart.
In order to achieve a stable heart rate (HR) at rest and to assure high quality recordings at comparable resting phases, all ECGs will be recorded for 10-sec duration after the patients have rested for at least [ADDRESS_1154925] during the recordings. ECG assessment will always precede all other study procedures (except PRO completion) of the same time point (except blood drawing from an intravenous cannula which is already in place) to avoid compromising the ECG quality.
Electrode placement will be performed according to the method of Wilson, Goldberger and 
Einthoven or limb leads modified by [CONTACT_656824] (hips and shoulders instead of ankles and wrists). 
ECGs will be recorded as single ECGs as indicated in the Flow Chart.
ECGs may be repeated for quality reasons for instance due to alternating current artefacts, muscle movements, or electrode dislocation. The repeat ECGs are assigned to the respective scheduled time point.
Additional (unscheduled) ECGs may be recorded for safety reasons. These ECGs are 
assigned to the prior scheduled time point in the sponsor’s database. 
Data transfer
All ECGs will be transferred electronically to the central ECG lab for storage and evaluation.
In case of repeat ECGs due to quality reasons, all ECGs will be transferred to the central 
ECG lab who will select the correct one for analysis. Unscheduled ECGs (for safety reasons) will be transferred to the central ECG lab but will not be included into the statistical analysis of interval lengths.
Evaluation
a) Central ECG lab
Central ECG lab evaluation will be performed for the pre dose ECGs.This will include the determination of cardiac QRS-axis as assessed by [CONTACT_221988]’s algorithm as well as the intervals RR, PR, QRS and QT measured semi-automatically.
Heart rate (HR) and the QT interval corrected for HR (QTc e.g. QTcF and QTcB) will be 
determined by [CONTACT_456] (see TSAP for details).
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 47 of 118
Proprietary confidential information © [ADDRESS_1154926]-03 (18.0) / Saved on: 10 Jul 2019All semi-automatic interval measurements in one petient will be performed on the same lead. The intervals will be measured from four cardiac cycles (beats) in lead II. If lead II shows a flat T wave or is not measurable for any reason, lead V5 will be used, or if that lead is not measurable, then lead I will be used. The lead actually used will be reported in the Clinical Trial Report.
For automatic interval measurements no lead will be provided.For blinding arrangements see section [IP_ADDRESS] . No more than two blinded readers will 
evaluate all ECGs of the study. ECGs from a particular patient should be evaluated by a 
single reader. For quality assurance and control of the measurements, all ECGs of a patient will be subsequently reviewed by [CONTACT_832074]/her designee to assess the overall variance of the measured intervals and, to detect accidental switching of leads and/or false patient assignments of the ECGs. After quality control, the fiducial point markings will be reviewed by [CONTACT_832075].Evaluation of ECGs will comply with the ICH E14 guidance document and supplements [R07-4722 , R16-0366 ] as well as the FDA requirements for annotated digital ECGs [ R09-
4830 ].
b) Trial site
All ECGs will be evaluated by [CONTACT_1720] a designee.For the inclusion or exclusion (see section 3.3 ) of a patient and for the assessment of 
cardiac safety during the study, the QT and QTc values generated by [CONTACT_832076]. In doubtful cases, ECGs may be sent upfront for centralised evaluation. In this case, these centrally measured results would overrule any other results obtained.
Abnormal findings, irrespective of whether they originate from central or local evaluation, will be reported as AEs (during the trial) or baseline conditions (at screening) if judged clinically relevant by [CONTACT_093]. Any ECG abnormalities will be monitored carefully and, if necessary, the patient will be removed from the trial and will receive the appropriate medical treatment.
Suicidal risk assessed by [CONTACT_941] C-SSRS
5.2.[ADDRESS_1154927] [ R17-1539 ];[R17-1540] and
roflumilast [ R17-1542 ] an increased risk of suicidality has been described. Therefore
prospective suicidality monitoring, will be performed throughout this trial using theColumbia Suicidal Severity Rating scale (C-SSRS).
The C-SSRS is a semi-structured, investigator-rated interview, developed by [CONTACT_342349], assessing both suicidal behavior and suicidal ideation. It does not give a global score, but provides some categorical and some severity information specifically for behavior and ideation.
The C-SSRS has been widely used in large multinational clinical trials. The C-SSRS will
be administered at the screening visit (using the ‘screening’ version) with the aim to exclude 
patients suicidal ideation type 4 to5 within the preceding 3 months or at Visit 1 or any 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 48 of 118
Proprietary confidential information © [ADDRESS_1154928]-03 (18.0) / Saved on: [ADDRESS_1154929] 2 years. The life time history of suicidal ideation and behavior will also be recorded.
After the screening/baseline visit the assessment ‘since last visit’ will be performed at each 
clinic visit (‘since last visit’ version).
For details on how C-SSRS will be assessed, refer to 2.
appendix 10.
C-SSRS results will be reported in terms of AEs as described in Section [IP_ADDRESS].4.
Assessment of adverse events 5.2.6
[IP_ADDRESS] Definitions of AEs
[IP_ADDRESS].[ADDRESS_1154930] a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):
∀Worsening of the underlying disease or of other pre-existing conditions 
∀Changes in vital signs, ECG, physical examination and laboratory test results, if they 
are judged clinically relevant by [CONTACT_093].
If such abnormalities already exist prior to trial inclusion, they will be considered as baseline conditions and should be collected in the eCRF only.
[IP_ADDRESS].2 Serious adverse event
A serious adverse event (SAE) is defined as any AE, which fulfils at least one of the following criteria:
- results in death,- is life-threatening, which refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hypothetically might have caused death if more severe,
- requires inpatient hospi[INVESTIGATOR_15574]- results in persistent or significant disability or incapacity,- is a congenital anomaly / birth defect,- is deemed serious for any other reason if it is an important medical event when based 
on appropriate medical judgement which may jeopardise the patient and may require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definitions. Examples of such events are intensive treatment in an emergency 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 49 of 118
Proprietary confidential information © [ADDRESS_1154931]-03 (18.0) / Saved on: 10 Jul 2019room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_23236]. 
For Japan only: the following events will be handled as “deemed serious for any other reason”. AEs which possibly lead to disability will be reported as SAEs.
[IP_ADDRESS].3 AEs considered “Always Serious”
In accordance with the European Medicines Agency initiative on Important Medical Events, Boehringer Ingelheim has set up a list of AEs, which by [CONTACT_15623], can always be considered to be “serious” even though they may not have met the criteria of an SAE as defined above.The latest list of “Always Serious AEs” can be found in the eDC system. A copy of the latest list of “Always Serious AEs” will be provided upon request. These events should always be reported as SAEs as described in section [IP_ADDRESS].
Cancers of new histology and exacerbations of existing cancer must be classified as a serious event regardless of the time since discontinuation of the drug and must be reported as described in section [IP_ADDRESS], subsections “AE Collection” and “ AE reporting to sponsor and 
timelines”.
[IP_ADDRESS].[ADDRESS_1154932] 
be reported as separate SAEs by [CONTACT_093].
For ‘self-injurious behavior, no suicidal intent’(type 11) standard AE/SAE reporting rules are to be applied.
For each negative report (Suicidal ideation type 1, 2 or 3) after the start of the trial, the 
investigator is to decide based on clinical judgement whether it represents an adverse event (AE) as defined in the protocol, and if it is considered an AE then it must be reported accordingly.
[IP_ADDRESS].[ADDRESS_1154933] recent definition of acute IPF exacerbation will be used [ P16-[ZIP_CODE] ]. The AEs will 
not be adjudicated. 
Acute exacerbation will be defined as an acute, clinically significant, respi[INVESTIGATOR_832053]:
∀Acute worsening or development of dyspnea typi[INVESTIGATOR_832054].
∀Computed tomography with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with IPF.
∀Deterioration not fully explained by [CONTACT_21641].
This event must be reported “acute exacerbation of disease under investigation”.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 50 of 118
Proprietary confidential information © [ADDRESS_1154934]-03 (18.0) / Saved on: [ADDRESS_1154935] be reported as “suspected acute 
exacerbations of disease under investigation” (as long as this assessment persists).
[IP_ADDRESS].[ADDRESS_1154936] (AESI) relates to any specific AE that has been 
identified at the project level as being of particular concern for prospective safety monitoring and safety assessment within this trial, e.g. the potential for AEs based on knowledge from other compounds in the same class. AESIs need to be reported to the sponsor’s Pharmacovigilance Department within the same timeframe that applies to SAEs, please see section [IP_ADDRESS].2 .
The following are considered as AESIs:
Hepatic injury
A hepatic injury is defined by [CONTACT_35961]: 
∀an elevation of AST (Aspartate Aminotransferase) and/or ALT (Alanine 
Aminotransferase) ≥[ADDRESS_1154937] combined with an elevation of total bilirubin ≥[ADDRESS_1154938] measured in the same blood draw sample, or
∀aminotransferase (ALT, and/or AST) elevations ≥[ADDRESS_1154939].
These lab findings constitute a hepatic injury alert and the patients showing these lab 
abnormalities need to be followed up according to the “DILI checklist” provided via eDC.In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the investigator should make sure these parameters are analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the procedures described in the DILI checklist should be followed.
Vasculitis events 
In this trial protocol vasculitis is defined as any event term included in the MedDRA SMQ 
Vasculitis (broad). This includes clinical and pathological features related to primary or secondary vasculitis syndromes and involving any type, size, and location of blood vessels.
[IP_ADDRESS].7 Intensity (severity) of AEs
The intensity (severity) of the AE should be judged based on the following:
Mild: Awareness of sign(s) or symptom(s) that is/are easily tolerated.
Moderate: Sufficient discomfort to cause interference with usual activity.Severe: Incapacitating or causing inability to work or to perform usual activities.
[IP_ADDRESS].8 Causal relationship of AEs
Medical judgement should be used to determine whether there is a reasonable possibility of a 
causal relationship between the adverse event and the given study treatment, considering all 
relevant factors, including pattern of reaction, temporal relationship, de-challenge or re-
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 51 of 118
Proprietary confidential information © [ADDRESS_1154940]-03 (18.0) / Saved on: [ADDRESS_1154941] that there is a reasonable possibility of a causal relationship 
could be:
∀The event is consistent with the known pharmacology of the drug.
∀The event is known to be caused by [CONTACT_23320].
∀A plausible time to onset of the event relative to the time of drug exposure.
∀Evidence that the event is reproducible when the drug is re-introduced.
∀No medically sound alternative aetiologies that could explain the event (e.g. pre-
existing or concomitant diseases, or co-medications).
∀The event is typi[INVESTIGATOR_23239]-related and infrequent in the general population not exposed to drugs (e.g. Stevens-Johnson syndrome).
∀An indication of dose-response (i.e. greater effect size if the dose is increased, smaller effect size if dose is reduced).
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be:
∀No plausible time to onset of the event relative to the time of drug exposure is evident (e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks of drug administration; an allergic reaction weeks after discontinuation of the drug concerned).
∀Continuation of the event despi[INVESTIGATOR_15576], taking into 
account the pharmacological properties of the compound (e.g. after 5 half-lives).
Of note, this criterion may not be applicable to events whose time course is prolonged despi[INVESTIGATOR_15577].
∀Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned).
∀Disappearance of the event even though the trial drug treatment continues or remains 
unchanged.
[IP_ADDRESS] Adverse event collection and reporting
[IP_ADDRESS].[ADDRESS_1154942] be collected and documented on the appropriate CRF(s) by [CONTACT_093]:• From signing the informed consent onwards until the individual patient’s end of trial (the 
End of Trial (EoTrial) visit): all AEs (serious and non-serious) and all AESIs.
• After the individual patient’s end of trial: 
the investigator does not need to actively monitor the patient for new AEs but should only report any occurrence of cancer and trial treatment related SAEs and trial treatment 
related AESIs of which the investigator may become aware of by [CONTACT_832077] 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 52 of 118
Proprietary confidential information © [ADDRESS_1154943]-03 (18.0) / Saved on: 10 Jul 2019communication, e.g. phone call. Those AEs should be reported on the BI SAE form (see section [IP_ADDRESS].2), but not on the CRF.
[IP_ADDRESS].[ADDRESS_1154944] report SAEs, AESIs, and non-serious AEs which are relevant for the reported SAE or AESI, on the BI SAE form immediately (within 24 hours) to the sponsor’s unique entry point (country specific contact [CONTACT_15626]). The same timeline applies if follow-up information becomes available. In specific occasions, the investigator could inform the sponsor upfront via telephone. This does not replace therequirement to complete the BI SAE form.
With receipt of any further information to these events, a follow-up SAE form has to be 
provided. For follow-up information the same rules and timeline apply  as for initial 
information. All (S)AEs, including those persisting after individual patient’s end of trial must be followed up until they have resolved, have been assessed as “chronic” or “stable” , or no further information can be obtained.
[IP_ADDRESS].[ADDRESS_1154945] report any drug exposure during pregnancy in a trial participant immediately (within 24 hours) by [CONTACT_15627] A of the Pregnancy Monitoring Form to the sponsor’s unique entry point.
Similarly, potential drug exposure during pregnancy must be reported if a partner of a male 
trial participant becomes pregnant. This requires written consent of the pregnant partner.Reporting and consenting must be in line with local regulations. The ISF will contain the trial specific information and consent for the pregnant partner.
The outcome of the pregnancy associated with the drug exposure during pregnancy must be 
followed up and reported to the sponsor’s unique entry point on the Pregnancy Monitoring Form for Clinical Studies (Part B).The ISF will contain the Pregnancy Monitoring Form for Clinical Studies (Part A and B).
As pregnancy itself is not to be reported as an AE, in the absence of an accompanying SAE 
and/or AESI, only the Pregnancy Monitoring Form for Clinical Studies and not the SAE form is to be completed. If there is an SAE and/or AESI associated with the pregnancy an SAE form must be completed in addition.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 53 of 118
Proprietary confidential information © [ADDRESS_1154946]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 54 of 118
Proprietary confidential information © [ADDRESS_1154947]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 55 of 118
Proprietary confidential information © [ADDRESS_1154948]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE].6 OTHER ASSESSMENTS
One optional substudy
can be proposed to the patients in case the site where he/she 
participates takes part of it. 
Participating in this substudy is totally voluntary. Not participating in will not affect the participation to the main study.
24 hr Cough measurement (substudy at dedicated sites only)
5.6.1
Subjects with a VAS severity ≥25 mm (on a scale of 100 mm) will be eligible for this sub-
studyObjective cough count measurements will be collected over a 24-hour period via a device worn by [CONTACT_309506] [ADDRESS_1154949] 
methods. Refer to Section 3.2 for the discussion of the choice of FVC as primary endpoint. 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 56 of 118
Proprietary confidential information © [ADDRESS_1154950]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 57 of 118
Proprietary confidential information © [ADDRESS_1154951]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. INVESTIGATIONAL PLAN
6.1 VISIT SCHEDULE
The acceptable time windows for visits are given in the Flow Chart.
Study measurements and assessments scheduled to occur ‘before’ trial medication 
administration on Day 1 are to be performed and completed within a 2 h-period prior to the 
trial drug administration ).
If several measurements including venepuncture are scheduled for the same time, 
venepuncture should be the last of the measurements due to its inconvenience to the patient and possible influence on physiological parameters.
 
 
If a patient misses an appointment, it will be rescheduled if possible. The re levance of 
measurements outside the permitted time windows will be assessed no later than at the Report Planning Meeting.
In exceptional cases, if standard visits at the trial sites are impossible because of COVID-19 
related safety risks, visits 3, 4, 5 and 7 may be performed at the patients’s home or remotelyvia telephone and/or internet means of communication.
The visits may also be performed as a combination of home and remote visits.
All home/remote visits need to be discussed with and approved by [CONTACT_456]`s trial team. 
Local regulatory and legal requirements of the participating country still apply.
For the details of the modifications refer to Section 6.2 .  
All COVID-19 related deviations from the original schedule of visits and procedures will be 
documented and the implications considered for the analysis of the trial data.
6.2 DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS
The following sequence of procedures at each visit (where applicable) is recommended:
Timing at Visit Days Procedures
Pre-dose ∀  
∀Blood sampling including predose  
Serum/Plasma and DNA sampling.
∀ECG 
∀FVC 
∀DLCO 
∀Time record of pre-dose blood collection.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 58 of 118
Proprietary confidential information © [ADDRESS_1154952]-03 (18.0) / Saved on: 10 Jul 2019∀IRT call
∀ Pre-dose or 
Post-dose∀
∀Physical examination including vital signs and body weight [at 
baseline only: demographics, medical history including pre-existing 
conditions]
∀AE and concomitant therapy collection, smoking status [at baseline 
only: treatment history]
∀C-SSRS questionnaire.
∀
∀Treatment dispense and administration of trial drug  
∀  
Screening period 6.2.1
Screening Period
After having been informed about the trial, all patients will be required to give written 
informed consent in accordance with ICH-GCP and local legislation prior to enrolment in the study. 
After informed consent is obtained, inclusion and exclusion criteria should be checked 
according to Flow Chart.
At selected sites performing Digital lung Auscultation substudy, patients should be invited 
during the informed consent process to participate in the respective substudy.
At selected sites performing 24hr Cough Measurement substudy, patients should be invited 
during the informed consent process to participate in the respective substudy.
Patients will be asked to give informed consent to the DNA, Plasma and Serum banking 
samples (please note: the banking samples must not be taken prior to Visit 2). Participation is voluntary and is not a prerequisite for participation in the trial.
 
 
For information regarding laboratory  tests
, ECG, vital signs, body weight and physical 
examination, refer to sections 5.2.1 to section 5.2.4.
For information on spi[INVESTIGATOR_038] (FEV 1 and FVC) and DLCO refer to section 5.1.1 , 5.1.2 and 
3. appendix 10.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 59 of 118
Proprietary confidential information © [ADDRESS_1154953]-03 (18.0) / Saved on: [ADDRESS_1154954] be repeated before the randomisation visit (Visit 2).
Treatment period
6.2.[ADDRESS_1154955] dose of BI 1015550 or placebo the morning of Visit 2 (Day 
1). Patients will take BI 1015550 18 mg (or placebo) twice daily (b.i.d) from Day [ADDRESS_1154956] it in case it expi[INVESTIGATOR_832055].
FVC has to be measured at the same time each visit ± 90 min (reference time at Visit 2).
DLCO should be done after FVC measurements. If it is done timely close to FVC 
measurement, patients should have the possibility to rest in between.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 60 of 118
Proprietary confidential information © [ADDRESS_1154957]-03 (18.0) / Saved on: [ADDRESS_1154958] may need to be adjusted and 
remote visits may be performed for Visits 3, 4, 5 and/or 7 if necessary.   
If a patient is not able to come to the site for a trial visit, a remote visit (by [CONTACT_832078]) should be performed instead. At minimum, the following assessment should be done: adverse events (AE, SAE, AESIs), C-SSRS, concomitant therapy , safety 
laboratory testing ,trial medication compliance check . Patients can report and/or send 
photos of trial medication kit used to their site staff, if needed and possible.
If blood sampling for central lab at the trial site is not possible, safety lab analyses can be 
performed at a local lab. The results of the lab tests must be transferred to the investigator who ensures medical review and documents a clinically relevant safety issue as an adverse event. Minimum required safety lab parameters are listed in Table [IP_ADDRESS] . 
If home visits are possible (preferable option), some assessments can be done at the patient’s home (e.g. collection of blood and urine samples to be sent to the central lab, vital signs).
Applicable to Visits 4, 5: If a patient is not able to come as planned but the investigator
considers it favorable and safe for the patient to continue on trial medication, the trialmedication can be shipped from site directly to the patient (if acceptable according to locallaws and regulations (see section 4.1.4 ). In this case, patients must consent to providing 
contact [CONTACT_230833][INVESTIGATOR_832056]. Investigators should conduct phone visits first to discuss adverse events, concomitant therapi[INVESTIGATOR_014], C-SSRS, assess trial medicationcompliance and have reviewed (local) safety laboratory results.

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 61 of 118
Proprietary confidential information © [ADDRESS_1154959]-03 (18.0) / Saved on: 10 Jul 2019Table 6.2.2:[ADDRESS_1154960] name 
[CONTACT_577121] (RBC)Reticulocyte count
White blood cell count (WBC)Platelet count
Erythrocyte sedimentation rate (ESR)
Coagulation Activated partial thromboplastin time (aPTT)
Prothrombin time (Quick’s test and INR)
Fibrinogen
Enzymes Aspartate transaminase (AST/GOT)
Alanine transaminase (ALT/GPT)Alkaline phosphatase (AP)Gamma-glutamyl transferase (GGT)Creatine kinase (CK)
CK-MB, only if CK is elevated 
Lactate dehydrogenase (LDH)
Lipase
SubstratesAmylase
Creatinine Total bilirubin Total protein
High sensitivity C-Reactive Protein (hs CRP)
Albumin
Electrolytes Sodium
Potassium
Chloride
Calcium
Inorganic phosphate
Urine analysis
(semi-quantitative measurements; -, +, 
++, +++)pH
Glucose
Erythrocytes
Leukocytes
Protein 
Nitrite
Follow-up period and trial completion 6.2.3
A follow up period of a minimum of 7 days (+3 days) will be required. All patients will 
complete an end of trial visit. For AE assessment, laboratory tests, recording of ECG and vital signs, and physical examination during the end of trial period, see sections 5.2.2 to 5.2.4.
All abnormal values (including laboratory parameters) that are judged clinically relevant by [CONTACT_656830] a return to a medically 
acceptable level is achieved. All (S)AEs persisting after individual patient’s end of trial must 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 62 of 118
Proprietary confidential information © [ADDRESS_1154961]-03 (18.0) / Saved on: [ADDRESS_1154962] been assessed as “chronic” or “stable” , or no further information can be obtained.
The end of the trial is defined as the date of the last visit of the last patient in the whole trial
(“Last Patient Completed”). 
Optional substudy
6.2.[ADDRESS_1154963] and will give their consent by a separate patient information / 
informed consent (PI / IC).
Participation in the substudy is voluntary and not a prerequisite for participation in the main 
trial. Participation in the main trial must not be affected if a patient withdraws from substudy 
participation.
Scheduling of optional substudy procedures is specified in the Flow Chart .
Substudy information for respective sites will be provided in the ISF.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 63 of 118
Proprietary confidential information © [ADDRESS_1154964]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
The primary endpoint is the change from baseline in FVC at week 12. This endpoint will be evaluated separately per strata, in the patient group with antifibrotic treatment and in the patient group with no antifibrotic treatment. The purpose of this trial is to demonstrate proof of concept of clinical activity of BI 1015550 on the primary endpoint. For the proof of concept an evaluation of a minimum relevant additional benefit of BI 1015550 compared to placebo is conducted. Hereby, the posterior probability of the difference in change from baseline in FVC between BI 1015550 and placebo will be evaluated for different boundary values Δ.
Historical information for the placebo group (separately for patients treated with antifibrotic 
treatment and patients not treated with antifibrotic treatment) will be taken into account via the usage of a Bayesian approach with informative priors. The results in both patient groups will then be combined to assess if proof of concept could be shown. 
7.1 NULL AND ALTERNATIVE HYPOTHESES
No hypothesis testing will be performed in the confirmatory sense. All the analyses will be 
performed in an exploratory fashion to better understand the efficacy and safety profile of BI 1015550.The primary analysis on the primary endpoint will be based on a Bayesian borrowingapproach.
7.2 PLANNED ANALYSES
General considerations
7.2.1
The following analysis sets will be defined for statistical analyses:
Entered Set (ES): This patient set includes all patients who signed informed consent. The ES 
will be used for the analysis of protocol deviations.Randomised Set (RS): This patient set includes all entered and randomised patients. The RS 
will be used for the analyses of patient disposition.Treated Set (TS): This patient set includes all patients who received at least one dose of study 
drug. The TS is used for safety analyses as well as demographics and baseline characteristics.Full Analysis Set (FAS): This patient set includes all patients in the TS who had a baseline 
and at least one post-baseline measurement available for FVC, FEV1 or DLCO. Patients in 
FAS are analyzed based on the trial medication they have actually received. The FAS is the main analysis set for the analysis of efficacy.
Per protocol set (PPS): includes all patients from the FAS without important protocol 
deviations (IPD) leading to exclusion from PPS. The PPS is used for efficacy analyses.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 64 of 118
Proprietary confidential information © [ADDRESS_1154965]-03 (18.0) / Saved on: [ADDRESS_1154966] ed but not included in any
summary statistics or inferential statistics. Specifications of important protocol deviations 
leading to exclusion will be provided in the trial Integrated Quality
 and Risk Management 
Plan (IQRMP) and all decisions concerning IPDs will be made before un-blinding.
Further Analysis Sets will be defined in the TSAP, if needed.
Primary endpoint analyses 7.2.[ADDRESS_1154967] dose of study medication, or screening data if visit 2 data are missing.
To account for the repeated nature of the data and the covariates in the model, MMRM 
analysis will be carried out for change from baseline of FVC after 12 weeks of treatment The adjusted mean change from baseline (and the related standard error) will be calculated for each group and will be used for the Bayesian borrowing approach [ R16-0278 ], [R16-
0281 ].
In order to evaluate the treatment effects, historical data from the nintedanib development program in IPF will be included for the placebo groups in each stratum and posterior probabilities for the treatment difference of BI [ADDRESS_1154968] to the primary endpoint will be estimated. The median of the posterior probability (and 95% credible intervals) will be calculated.
The analysis will include the fixed, categorical effect of treatment at each visit, and the fixed 
continuous effects of baseline FVC at each visit. Visit will be treated as the repeated measure with an unstructured covariance structure used to model the within-patient measurements.
Procedures to follow if the analysis fails to converge will be described in the TSAP.
 
 
 
 
 
 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 65 of 118
Proprietary confidential information © [ADDRESS_1154969]-03 (18.0) / Saved on: [ADDRESS_1154970] assuming all patients took randomized treatment for the duration of the trial
using a hypothetical approach, i.e. trial drug is taken as directed. The primary analysis of the 
primary endpoint will include all data collected while on treatment. Any data collected at the follow up will not be included in the primary analysis. The resulting missing data will be assumed to be missing at random (MAR). Patients will be analysed according to the stratum 
to which they belong (regardless of any mis-assignment to treatment based on identification 
of the wrong stratum), as such an error occurs before randomisation and is therefore consistent with regulatory guidance.
 
 
 
[IP_ADDRESS] Prior derivation
For both placebo groups (on antifibrotics and not on antifibrotics), an informative prior will 
be used based on historical data from the nintedanib development program in IPF. 
The derivation of the informative prior is based on a meta-analytic predictive (MAP) prior 
approach, where a vaguely informative mixture component is added to the prior to obtain a 
prior which is robust against prior-data conflicts. 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 66 of 118
Proprietary confidential information © [ADDRESS_1154971]-03 (18.0) / Saved on: 10 Jul 2019For the comparison of the BI 1015550 treatment with placebo, the posterior probability of the 
difference in change from baseline in FVC between BI 1015550 and placebo will be 
evaluated. This evaluation will be done based on the posterior probability P( BI – PBO > Δ
ml | Data) > x using predefined thresholds Δand x.
For the primary endpoints defined in Section 2.1.[ADDRESS_1154972] deviations for the prior calculation are given in Table [IP_ADDRESS]: 1below.
Table [IP_ADDRESS]: [ADDRESS_1154973] deviations
Study*Placebo group of patients not on 
antifibrotic treatmentPlacebo group of patients on 
antifibrotic treatment
Nadj. mean change from 
baseline at week 12 (SE)Nadj. mean change from 
baseline at week 12 (SE)
1199_0032 204 -71.45 (12.53) 307 -20.13 (10.22)
1199_0034 216 -87.89 (12.23) 327 -33.10 (9.97)
1199_187P1 53 -31.79 (24.33) 53 12.97 (24.33)
1199_227 230 -72.93 (12.53) 116 -1.98 (17.48)
1199_30 85 -81.54 (24.00) 84 0.09 (24.10)
1199_222 NA NA 51 -29.77 (25.95)
1199_0036 NA NA 135 -25.65 (15.82)
*Based on unpublished data. Trials were reanalysed using the analysis model planned for the 
primary analysis
The estimates from Table [IP_ADDRESS]: 1 were used to generate informative priors for the two 
placebo groups (patients on antifibrotic treatment at baseline and patients not on antifibrotic treatment at baseline) based on a meta-analytic predictive (MAP) prior approach, where a vaguely informative mixture component is added to the prior to obtain a prior which is robust against prior-data conflicts [ R16-0281 ]. Thus, the prior is a mixture of informative and non-
informative beta priors and the weight of the non-informative beta prior is 50%. This prior is further downweighted by [CONTACT_832079] (to allow for the new data to have a sufficient weight). Therefore, the actual prior considered for the placebo group of patients not on antifibrotic treatment at baseline is (mixture normal distributed prior with 3 informative and 1 vaguely informative components):
 
 ,    ~0 . 2 8 N (−74.0, 16.1 )+0 . 1 9 (−71.1, 42.2 )+0 . 0 3 (−70.2, 97.8 )
+0 . 5 (−73.0, 315.7)
Likewise for the placebo group of patients on antifibrotic treatment at baseline the prior is 
given as
  ,  ~0 . 2 7 N (−20.0, 16.2 )+0 . 2 0 (−17.0, 39.8 )+0 . 0 3 (−15.4, 87.7 )
+0 . 5 (−19.0, 385.7)
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 67 of 118
Proprietary confidential information © [ADDRESS_1154974]-03 (18.0) / Saved on: [ADDRESS_1154975] of a mixture of 
priors:
   ,      ~ N (−73.0, 315.7 )
    ,    ~ N (−19.0, 385.7 )
Details for the prior calculation can be found in Appendix 10.9.
The actual prior may be updated based on additional historical information being available 
before the trial starts. The final prior will be documented in the TSAP. All analyses based on informative priors will be repeated with vaguely informative priors as well to ensure comparability with a frequentist setting.
 
.
Secondary endpoint analyses
7.2.3
The analysis of the secondary endpoint percentage N (%) of patients with Treatment 
Emergent Adverse Events (TEAE) will be described in Section 7.2.5 .

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 68 of 118
Proprietary confidential information © [ADDRESS_1154976]-03 (18.0) / Saved on: 10 Jul 2019Safety analyses 7.2.5
Adverse events will be coded using the Medical Dictionary for Drug Regulatory Activities(MedDRA). Standard BI summary tables and listings will be produced. All adverse events with an onset between start of treatment and end of the REP, a period of [ADDRESS_1154977] drug intake and deteriorate under treatment will also be considered as ‘treatment-emergent’.
Frequency, severity, and causal relationship of adverse events will be tabulated by [CONTACT_195912] (MedDRA) at database lock.
Laboratory data will be analysed both quantitatively as well as qualitatively. The latter will 
be done via comparison of laboratory data to their reference ranges. Values outside the reference range as well as values defined as clinically relevant will be summarised. Treatment groups will be compared descriptively with regard to distribution parameters as well as with regard to frequency and percentage of patients with abnormal values or clinically relevant abnormal values.
Vital signs, physical examinations, or other safety-relevant data observed at screening, 
baseline, during the course of the trial and at the end-of-trial evaluation will be assessed with regard to possible changes compared to findings before start of treatment.
Further details will be provided in the TSAP.
Other Analyses
7.2.6
[IP_ADDRESS] Pharmacokinetic methods
In the Clinical Trial Report, plasma concentrations of BI [ADDRESS_1154978] proceeds to a next phase, a population pharmacokinetic analysis will be performed on BI 1015550 plasma concentrations. 
A separate Population PK Analysis Plan will be written, and results will be reported
separately.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 69 of 118
Proprietary confidential information © [ADDRESS_1154979]-03 (18.0) / Saved on: 10 Jul 2019Interim Analyses 7.2.7
No interim analysis is planned but a Data Monitoring Committee (DMC) will be in place with tasks as described in section 8.[ADDRESS_1154980] model will handle missing data based on a likelihood method under the "missing at random assumption". This means e.g. patients with missing data would have behaved similarly to patients with observed data.
Missing or incomplete AE dates will be imputed according to BI standards. 
Handling of missing data for secondary endpoints as well as for sensitivity analysis will be 
described in the TSAP.
The handling of missing data for the Population PK Analysis is described in a separate
PopPK Analysis Plan.
7.4 RANDOMISATION
Patients will be randomised to one of the treatment arms in a 2:1 ratio (BI 1015550 18 mg / 
placebo, all b.i.d), with approximately 100 patients in the BI dose group and approximately 50 patients in the placebo group (total maximum 150 patients). Randomisation will be stratified by [CONTACT_832080] (patients treated with antifibrotic treatment vs patients not treated with antifibrotic treatment at baseline).
The Randomisation of patients to the treatment groups will be performed via an interactive 
response technology (IRT). This system will also include caps for use of antifibrotic treatment to ensure a certain balance required for the evaluation of the study objectives. In particular a minimum number of [ADDRESS_1154981] 60 in the patient group with no antifibrotic treatment, from a total of approximately 150 patients with a 1:2 ratio between placebo and BI 1015550.Calculations below are based on the minimum of 120 patients.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 70 of 118
Proprietary confidential information © [ADDRESS_1154982]-03 (18.0) / Saved on: 10 Jul 2019The sample size for the patient group not treated with antifibrotic treatment is based on the following evaluations of the posterior probabilities (see also Table 7.5:2 ). Hereby [CONTACT_832081].
However, the expected treatment effect of BI 1015550 vs. Placebo in addition to antifibrotic 
treatment is expected to be low after 12 weeks of treatment as the expected decline in FVC is only 20mL at 12 weeks. Therefore, the main driver for the decision probabilities presented below is the group without antifibrotic treatment at baseline.
The sample size of this trial is based on evaluation of the observed treatment effects in
patients with and without antifibrotic treatment at baseline. In order to evaluate the treatment effects, historical data from the nintedanib development program in IPF will be included for the placebo groups in each stratum and posterior probabilities P( BI – PBO > 50mL | Data) for the treatment difference of BI [ADDRESS_1154983] in the following. A stepwise approach will be used to assess the observed treatment effects within the strata:
1.Treatment effect within the stratum without antifibrotic treatment only:
The observed treatment effect will be compared to a certain minimum treatment effect 
Δ
nAF(e.g. 50mL) in the group without antifibrotic treatment (independent of the 
observed treatment effect in the group with antifibrotic treatment)
2.Treatment effect within the stratum without antifibrotic treatment and with antifibrotic treatment:
In a second step, if the treatment effect observed in the group without antifibrotic 
treatment is lower than Δ
nAF, but higher than another threshold ΔCnAF <= Δ nAF(e.g. 
35mL), then  the group with antifibrotic treatment will be taken into account and the observed treatment effect in the patient group with antifibrotic treatment will be compared to a certain minimum treatment effect Δ
CAF(e.g. 30mL) ,see Table 7.5: [ADDRESS_1154984] based on the two patient groups means.
Table 7.5: [ADDRESS_1154985] of BI 1015550 based on the two patients groups with 
and without antifibrotic treatment 
Change from baseline in FVC [ml] 
at week 12 in patients not on antifibrotic treatmentChange from baseline in FVC [ml] at week 12 in patients on antifibrotic 
treatment
Not on antifibrotics 
criterion≥50 mL -
Combined criterion ≥ 35 mL ≥30 mL
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 71 of 118
Proprietary confidential information © [ADDRESS_1154986]-03 (18.0) / Saved on: 10 Jul 2019The assumed sample sizes for BI 1015550 18 mg b.i.d and placebo group (in both strata onantifibrotic treatment and without antifibrotic treatment) are 40 and 20, respectively, and historical information for the placebo groups (with an effective sample size of approximately 20 for each stratum) is included via Bayesian borrowing. 
For example, if there is a true treatment difference of 70 mL in change from baseline in the 
not on antifibrotics group (assuming a disease progression of approx. -73mL over [ADDRESS_1154987] deviation of 200 mL in both groups) , and a true treatment difference of 20 mL in change from baseline in the antifibrotics group (assuming a disease progression of approx. -19mL over [ADDRESS_1154988] deviation of 200 mL in both groups), the probability is 75% to observe a treatment effect of > 50 mL in the not on antifibrotics group or >[ADDRESS_1154989] of > 30 mL in the antifibrotics group (based on the two 
criteria specified in Table 5.2.3: 1 ). If there is actually no true treatment difference in both 
groups, such sample size provides a chance of 89% to observe either a treatment effect of <35 mL in the not on antifibrotics group or <[ADDRESS_1154990] of <[ADDRESS_1154991] sizes. 
The results are given in Table 7.5: 2 for a randomisation ratio of 1:2.
Table 7.5: 2 Outcome probabilities for each scenario under different settings (including 
historical information via information prior for the Pbo group) assuming a SD of 200 ml and 20+H/40 patients on PBO/BI [ADDRESS_1154992]
SizesN in each 
stratum P(Outcome +
#) P(Outcome -#) P(Outcome +/-)
Without
antifibrotics/ 
With 
antifibroticsWith/Without 
antifibrotics 
(Pbo/BI)
70mL/20mL 20+H/40 75% 11% 14%
60mL/15mL 20+H/40 65% 17% 18%
10mL/ 0mL 20+H/40 16% 60% 24%
0mL/ 0mL 20+H/40 11% 66% 23%
Numbers are each based on [ZIP_CODE] simulated trials for each scenario.
#Outcome +=not on antifibrotics or combined criterion are fulfilled, i.e,
∀Observed treatment effect for the not on antifibrotics group δnAF≥50mL OR
∀Observed treatment effect for the not on antifibrotics group δnAF≥35mL and 
observed treatment effect for the antifibrotics group δAF≥30mL
  Outcome -= Neither of the following two conditions is fulfilled, 
∀Observed treatment effect for the not on antifibrotics group δnAF≥35mL
∀Observed treatment effect for the antifibrotics group δ AF≥30mL   
  Outcome +/-: 
∀Observed treatment effect for the not on antifibrotics group 35mL ≤ δ nAF< 50mL and 
observed treatment effect for the antifibrotics group δAF <30mL OR 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 72 of 118
Proprietary confidential information © [ADDRESS_1154993]-03 (18.0) / Saved on: 10 Jul 2019∀Observed treatment effect for the not on antifibrotics group δnAF< 35mL and observed 
treatment effect for the antifibrotics group δAF ≥ 30mL.
+H=including historical information via informative prior (with an effective sample size of approximately 20).Calculations were based on R version 3.6.[ADDRESS_1154994] package.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 73 of 118
Proprietary confidential information © [ADDRESS_1154995]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND
ADMINISTRATIVE STRUCTURE
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU directive 2001/20/EC / EU regulation 536/2014, the Japanese GCP regulations (Ministry of Health and Welfare Ordinance No. 28, March 27, 1997) and other relevant regulations. Investigators and site staff must adhere to these principles. Deviation from the protocol, the principles of ICH GCP or applicable regulations as will be treated as “protocol deviation”.Standard medical care (prophylactic, diagnostic and therapeutic procedures) remains the responsibility of the treating physician of the patient.
The investigator will inform the sponsor immediately of any urgent safety measures taken to 
protect the trial patients against any immediate hazard, as well as of any serious breaches of the protocol or of ICH GCP.
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. The rights of the investigator and of the sponsorwith regard to publication of the results of this trial are described in the investigator contract. As a rule, no trial results should be published prior to finalisation of the Clinical Trial Report.
The certificate of insurance cover is made available to the investigator and the patients, and is
stored in the ISF.
8.[ADDRESS_1154996] (IRB / Independent Ethics Committee (IEC and competent authority (CA) according to national and international regulations. The same applies for the implementation of changes introduced by [CONTACT_15635].
Prior to patient participation in the trial, written informed consent must be obtained from each 
patient (or the patient’s legally accepted representative) according to ICH-GCP and to the regulatory and legal requirements of the participating country. Each signature [CONTACT_23362] [CONTACT_23343]-information form retained by [CONTACT_23344]. A signed copy of the informed consent and any additional patient information must be given to each patient or the patient’s legally accepted representative.”
The investigator or delegate must give a full explanation to trial patients based on the patient
information form. A language understandable to the patient should be chosen, technical terms 
and expressions avoided, if possible. 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 74 of 118
Proprietary confidential information © [ADDRESS_1154997]-03 (18.0) / Saved on: [ADDRESS_1154998] be given sufficient time to consider participation in the trial. The investigator or delegate obtains written consent of the patient’s own free will with the informed consent form after confirming that the patient understands the contents. The investigator or  delegate must sign (or place a seal on) and date the informed consent form. If a trial collaborator has given a supplementary explanation, the trial collaborator also signs (or places a seal on) and dates the informed consent.
Re-consenting may become necessary when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.The consent and re-consenting process should be properly documented in the source documentation.
If study conduct may need to be adjusted during the COVID-19 pandemic (see Section 4.1.4
and Section 6.2 ), the patient must be made aware of any modifications and provide their
agreement to the modifications prior to them being implemented.
8.[ADDRESS_1154999], trial design 
or monitoring approaches.
A quality assurance audit/inspection of this trial may be conducted by [CONTACT_456], sponsor’s 
designees, or by [CONTACT_1744] / IEC or by [CONTACT_12721]. The quality assurance auditor will have access to all medical records, the investigator’s trial-related files and correspondence, and the informed consent documentation of this clinical trial.
8.3 RECORDS
CRFs for individual patients will be provided by [CONTACT_456]. See section [IP_ADDRESS] for rules 
about emergency code breaks. For drug accountability, refer to section 4.1.8 .
Source documents 8.3.1
For adverse events, an end date may not always be available (e.g. due to hospi[INVESTIGATOR_507315], or change in treating physician), but should be recorded in the source if known.For eCRF all data need to be derived from source documents, which need to be available on-site (this could be for example physician’s notes in patient files, printouts, patient diaries).
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trial records that include all observations and 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 75 of 118
Proprietary confidential information © [ADDRESS_1155000]-03 (18.0) / Saved on: 10 Jul 2019other data pertinent to the investigation on each trial patient. Source data as well as reported data should follow the “ALCOA principles” and be attributable, legible, c ontemporaneous, 
original and accurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must be explained.
The current medical history of the patient may not be sufficient to confirm eligibility for the 
trial and the investigator may need to request previous medical histories and evidence of any diagnostic tests. In this case, the investigator must make at least one documented attempt to retrieve previous medical records. If this fails, a verbal history from the patient, documented in their medical records, would be acceptable.
Copi[INVESTIGATOR_832057] (HRCT) necessary for central eligibility reads will be provided to an 
imaging vendor. Before sending or uploading those copi[INVESTIGATOR_014], the investigator must ensure that all patient identifiers (e.g. patient’s name, initials, address, phone number, social security number) have properly been removed or redacted from any copy of the patients’ source documents.
If the patient is not compliant with the protocol, any corrective action e.g. re-training must be 
documented in the patient file.
For the CRF, data must be derived from source documents, for example:
∀Patient identification: gender, year of birth (in accordance with local laws and 
regulations)
∀Patient participation in the trial (substance, trial number, patient number, date patient was informed)
∀Dates of patient’s visits, including dispensing of trial medication
∀Medical history (including trial indication and concomitant diseases, if applicable)
∀Adverse events and outcome events (onset date (mandatory), and end date (if available))
∀Serious adverse events (onset date (mandatory), and end date (if available))
∀Concomitant therapy (start date, changes)
∀Originals or copi[INVESTIGATOR_23242], with proper documented medical evaluation (in validated electronic format, if available)
∀Patient related outcome worksheet completed by [CONTACT_832082].
∀Completion of patient’s participation in the trial” (end date; in case of premature discontinuation document the reason for it).
∀Prior to allocation of a patient to a treatment into a clinical trial, there must be documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records, verbal documented feedback of the patient or testing conducted specific for a protocol) to support inclusion/exclusion criteria does not make the patient eligible for the clinical trial.
Direct access to source data and documents
8.3.2
The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review and regulatory inspections. Direct access must be provided to the CRF and all source 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 76 of 118
Proprietary confidential information © [ADDRESS_1155001]-03 (18.0) / Saved on: 10 Jul 2019documents/data, including progress notes, copi[INVESTIGATOR_15587], which must be available at all times for review by [CONTACT_2689], auditor and regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The accuracy of the data will be verified by [CONTACT_23350] 8.3.1 .T h e  
sponsor will also monitor compliance with the protocol and GCP.
Storage period of records 8.3.3
Trial site(s):
The trial site(s) must retain the source and essential documents (including ISF) according to contract or the local requirements valid at the time of the end of the trial (whatever is longer).Sponsor:
The sponsor must retain the essential documents according to the sponsor’s SOPs.
8.[ADDRESS_1155002] parties is prohibited with the following exceptions:Personalised treatment data may be given to the patient’s personal physician or to other appropriate medical personnel responsible for the patient’s welfare. Data generated at the siteas a result of the trial need to be available for inspection on request by [CONTACT_23351], the sponsor’s representatives, by [CONTACT_1201] / IEC and the regulatory authorities.
Collection, storage and future use of biological samples and corresponding 
8.5.[ADDRESS_1155003] to comply with the applicable rules for the collection, biobanking and future use of biological samples and clinical data, in particular
∀Sample and data usage has to be in accordance with the separate biobanking informed 
consent
∀The BI-internal facilities storing biological samples from clinical trial participants as well as the external banking facility are qualified for the storage of biological samples 
collected in clinical trials
∀An appropriate sample and data management system, incl. audit trail for clinical data and samples to identify and destroy such samples according to ICF is in place
∀A fit for the purpose documentation (biomarker proposal, analysis plan and report) 
ensures compliant usage
∀A fit for purpose approach will be used for assay/equipment validation depending on 
the intended use of the biomarker data
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 77 of 118
Proprietary confidential information © [ADDRESS_1155004]-03 (18.0) / Saved on: 10 Jul 2019∀Samples and/or data may be transferred to third parties and other countries as specified in the biobanking ICF
8.[ADDRESS_1155005] patient in the whole trial
(“Last Patient Completed”).The “ Last Patient Last Treatment” (LPLT) date is defined as the date on which the last 
patient in the whole trial is administered the last dose of trial treatment (as scheduled per protocol or prematurely). Individual investigators will be notified of S[LOCATION_003]Rs occurring with the trial medication until [ADDRESS_1155006].The IEC / competent authority in each participating EU member state will be notified about the trial milestones according to the respective laws.A final report of the clinical trial data will be written only after all patients have completed the trial in all countries (EU or non-EU) to incorporate and consider all data in the report.The sponsor will submit to the EU database a summary of the final trial results within one year from the end of a clinical trial as a whole, regardless of the country of the last patient(EU or non-EU).
8.7 ADMINISTRATIVE STRUCTURE OF THE TRIAL
The trial is sponsored by [CONTACT_23347] (BI).
A Coordinating Investigator [INVESTIGATOR_88800]. Tasks and responsibilities are defined in a contract. 
A DMC will be established. Members of the DMC are independent of BI, they are physicians 
experienced in the treatment of the disease under investigation and a statistician. The DMC will evaluate the entire safety data and will meet on an ongoing basis during the course of the trial. The DMC can receive urgent significant safety concerns for immediate evaluation. While DMC members may be unblinded, measures are in place to ensure the blinding for everyone else involved in the trial. Regular DMC meetings will be held at specified intervals. The DMC will recommend continuation, modification or termination of the trial as detailed in the DMC charter. DMC recommendations as well as the final BI decision will be reported to the appropriate Regulatory Authorities (RAs)/Health Authorities (HAs), IRBs/ECs, and to investigators as requested by [CONTACT_1769]. The tasks and responsibilities of the DMC are specified in a charter.
Relevant documentation on the participating (Principal) Investigators (e.g. their curricula 
vitae) will be filed in the ISF.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 78 of 118
Proprietary confidential information © [ADDRESS_1155007]-03 (18.0) / Saved on: [ADDRESS_1155008] access to the BI web portal Clinergize to access documents provided by [CONTACT_456].
BI has appointed a Clinical Trial Leader (CT Leader), responsible for coordinating all 
required activities, in order to 
- manage the trial in accordance with applicable regulations and internal SOPs,- direct the clinical trial team in the preparation, conduct, and reporting of the trial,- ensure appropriate training and information of Clinical Trial Managers (CT 
Managers), Clinical Research Associates (CRAs), and investigators of participating countries.
The organisation of the trial in the participating countries will be performed by [CONTACT_195913]-organisation (Operating Unit, OPU) in accordance with applicable regulations and BI SOPs, or by a Contract Research Organisation (CRO) with which the responsibilities and tasks will have been agreed and a written contract filed before initiation of the clinical trial.
Data Management and Statistical Evaluation will be done by [CONTACT_15640].Bioanalysis of BI [ADDRESS_1155009] of responsible persons and relevant local information can be found in the ISF.A central laboratory service, a central images service, a central ECG review service and an IRT vendor will be used in this trial. Details will be provided in the IRT Manual and Central Laboratory Manual, available in the ISF.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 79 of 118
Proprietary confidential information © [ADDRESS_1155010]-03 (18.0) / Saved on: 10 Jul [ZIP_CODE]. REFERENCES
9.1 PUBLISHED REFERENCES
P05-[ZIP_CODE] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, 
Crapo R, Enright P, Grinten CPM van der, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi 
G, Wanger J Standardisation of spi[INVESTIGATOR_038]. Eur Respir J 26 (2), 319 - 338 
(2005)
P13-[ZIP_CODE] Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW,
Vadivelu R, Vicknasingam BK, Amato D, Hoersten S von, Ismail NIW,Jayabalan N, Hazim AI, Mansor SM, Muller CP From Kratom tomitragynine and its derivatives: physiological and behavioural effectsrelated to use, abuse, and addiction. Neurosci Biobehav Rev 37 (2), 138 -151 (2013)
P16-[ADDRESS_1155011] HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al
Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report.
Am J Respir Crit Care Med 194 (3), 265 - 275 (2016)
R06-2002 Macintyre N, Crapo RO, Viegi G, Johnson DC, Grinten CPM van der, 
Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, 
Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J
Standardisation of the single-breath determination of carbon monoxide 
uptake in the lung.
Eur Respir J 26 (4), 720 - 735 (2005)
R06-[ADDRESS_1155012] ID
Development of a symptom specific health status measure for patients with 
chronic cough: Leicester Cough Questionnaire (LCQ).
Thorax 58 (4), 339 - 343 (2003)
R07-4722 Guidance for industry: E14 clinical evaluation of QT/QTc interval 
prolongation and proarrhythmic potential for non-antiarrhythmic drugs.Rockville: U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2005)
R09-4830 Brown BD, Badilini F
HL7 aECG implementation guide (March 21, 2005).
R10-1424 Pi[INVESTIGATOR_17872] J, Bornkamp B, Bretz F. Design and analysis of dose-finding
studies combining multiple comparisons and modeling procedures. J
Biopharm Stat. 2006. 16(5): 639-656.
R14-1197 Lehmacher W, Wassmer G. Adaptive sample size calculations in group
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 80 of 118
Proprietary confidential information © [ADDRESS_1155013]-03 (18.0) / Saved on: 10 Jul 2019sequential trials. Biometrics 1999; 55:1286–1290 R14-2334 Bretz, F. , Koenig, F. , Brannath, W. , Glimm, E. and Posch, M. (2009),Adaptive designs for confirmatory clinical trials. Statist. Med., 28: 1181-1217. doi:10.1002/sim.3538
R15-2001 Bornkamp B, Pi[INVESTIGATOR_17872] J, Bretz F. Package ‘DoseFinding’. Comprehensive 
R Archive Network. [ADDRESS_1155014] HR
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001 - 11. Lancet Respir Med 2, 566 - 572 (2014)
R14-[ADDRESS_1155015] century. Ann Am Thorac Soc 11 (8), 1176 - 1185 (2014)
R15-2010 Ferraz MB, Quaresma MR, Aquino LRL, Atra E, Tugwell P, Goldsmith 
CHReliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 17 (8), 1022 - 1024 (1990)
R16-0278 Neuenschwander B, Capkun-Niggli G, Branson M, Spi[INVESTIGATOR_59898]. 
Summarizing historical information on controls in clinical trials. Clin Trials 7(1), 5 - 18 (2010)
R16-0281 Schmidli H, Gsteiger S, Roychoudhury S, O'Hagan A, Spi[INVESTIGATOR_192636] D,
Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics 70, 1023 - 1032 (2014)
R16-0366 E14 Implementation Working Group
ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: questions & answers (R3) (current version dated 10 December 2015).
Geneva: International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (2015)
R16-1737 Esposito DB, Lanes S, Donneyong M, Holick CN, Lasky JA, Lederer D,
Nathan SD, O'Quinn S, Parker J, Tran TN Idiopathic pulmonary fibrosis in [LOCATION_002] automated claims: incidence, prevalence, and algorithmvalidation. Am J Respir Crit Care Med 192 (10), 1200 - 1207 (2015)
R17-1427 Otezla 10 mg, 20 mg, 30 mg film-coated tablets, Otezla 30 mg film-coated 
tablets (Celgene) (summary for product characteristics, manufacturer responsible for batch release, conditions or restrictions regarding supply and use, other conditions and requirements of the marketing authorisation, conditions or restrictions with regard to the safe and effective use of the medicinal product, labelling and package leaflet (first published 16/02/2015).
R17-1539 Otezla 30mg tablets (Celgene) (summary of product characteristics updated 
05-Jan-2017).
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 81 of 118
Proprietary confidential information © [ADDRESS_1155016]-03 (18.0) / Saved on: 10 Jul 2019R17-1540 Otezla 10mg, 20mg, 30mg treatment initiation pack (Celgene) (summary 
of product characteristics updated 05-Jan-2017).
R17-1542 Daxas 500 micrograms film-coated tablets ([COMPANY_008]) (summary of 
product characteristics updated 06-Dec-2016).
R17-4075 Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby [CONTACT_67382], Galvin JR, et 
al Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med, (2017)
R17-[ADDRESS_1155017] R, McKeever T Global incidence and
mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46 (3), 795 - 806 (2015)
R18-0408 Raghu G, Morrow E, Collins BF, Ho LAT, Hinojosa MW, Hayes JM, et al 
Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at asingle centre. Eur Respir J 48, 826 - 832 (2016)
R18-1413 Strongman H, Kausar I, Maher TM Incidence, prevalence, and survival of 
patients with idiopathic pulmonary fibrosis in the [LOCATION_006]. Adv Ther, (2018)
R18-2794 Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, 
et al, American Thoracic Society, European Respi[INVESTIGATOR_3764], Japanese Respi[INVESTIGATOR_3764], Latin American Thoracic Society Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198 (5), e44 - e68 (2018)
9.2 UNPUBLISHED REFERENCES
c24902949-01Final Clinical Trial Report (1305-0015) Relative bioavailability of a single oral dose of BI 1015550 when administered alone or in combination with multiple oral doses of itraconazole in healthy male subjects.  08Feb2019
c02094779 Investigator's Brochure BI 1015550 for Idiopathic Pulmonary Fibrosis. 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 82 of 118
Proprietary confidential information © [ADDRESS_1155018]-03 (18.0) / Saved on: 10 Jul 201910. APPENDICES

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 83 of 118
Proprietary confidential information © [ADDRESS_1155019]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 84 of 118
Proprietary confidential information © [ADDRESS_1155020]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 85 of 118
Proprietary confidential information © [ADDRESS_1155021]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 86 of 118
Proprietary confidential information © [ADDRESS_1155022]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 87 of 118
Proprietary confidential information © [ADDRESS_1155023]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 88 of 118
Proprietary confidential information © [ADDRESS_1155024]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 89 of 118
Proprietary confidential information © [ADDRESS_1155025]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 90 of 118
Proprietary confidential information © [ADDRESS_1155026]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 91 of 118
Proprietary confidential information © [ADDRESS_1155027]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 92 of 118
Proprietary confidential information © [ADDRESS_1155028]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 93 of 118
Proprietary confidential information © [ADDRESS_1155029]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 94 of 118
Proprietary confidential information © [ADDRESS_1155030]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 95 of 118
Proprietary confidential information © [ADDRESS_1155031]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 96 of 118
Proprietary confidential information © [ADDRESS_1155032]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 97 of 118
Proprietary confidential information © [ADDRESS_1155033]-03 (18.0) / Saved on: 10 Jul 201910.2 COLUMBIA SUICIDAL SEVERITY RATING SCALE (C-SSRS)
The C-SSRS is a brief measure which is designed to assess severity and change of suicidality
by [CONTACT_832083], behavior and ideation. The C-SSRS was designed to address the need for a summary measure to track change in the severity of suicidality across both clinical settingsand treatment trials.
The C-SSRS interview may be administered by [CONTACT_303712], psychologist, clinical 
social worker, mental health counsel or, nurse, or coordinator with C-SSRS training. It has a 
typi[INVESTIGATOR_417801], and causes only a low burden on patients. At a minimum, the interview consists of 2 screening questions related to suicidal ideation and 4 related to suicidal behavior and may be expanded to up to 17 items in case of positive responses. Free text entries are allowed for; the investigator has to directly evaluate the scale and write a report.The investigator is to review all positive and negative reports for plausibility and clinical relevance. Doubtful reports may be validated by a consulting psychiatrist. If there is a confirmed positive report of suicidal behavior or suicidal ideation type 4 or 5 after start of trial, the investigator is to immediately interview the patient during the clinic visit and/or is to consult a psychiatrist. If the positive report is confirmed, appropriate actions for the patient’s safety have to be initiated.
At screening, C-SSRS (screening version) will be used with the aim to exclude patients with 
suicidal ideation type [ADDRESS_1155034] 2 years.Subsequently, the C-SSRS “since last visit will be performed at the time points given in the Flow Chart. For assessment, paper forms will be used and results will be transcribed into the 
CRF.
All positive reports during trial treatment are treatment-emergent adverse events (AEs).
The results of further medical, including psychiatric examinations,Y should be documented as adverse events where appropriate.
The original Columbia Suicidal Severity Rating scales used in this trial are shown as follows:
- Visit 1 –Screening version
- Subsequent visits- Since last visit version.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 98 of 118
Proprietary confidential information © [ADDRESS_1155035]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 99 of 118
Proprietary confidential information © [ADDRESS_1155036]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 100 of 118
Proprietary confidential information © [ADDRESS_1155037]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 101 of 118
Proprietary confidential information © [ADDRESS_1155038]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 102 of 118
Proprietary confidential information © [ADDRESS_1155039]-03 (18.0) / Saved on: 10 Jul 2019

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 103 of 118
Proprietary confidential information © [ADDRESS_1155040]-03 (18.0) / Saved on: [ADDRESS_1155041] fulfil the following criteria:
∀Within range 25% - 80% predicted of normal; corrected for Hb
For predicted normal values, different sites may use different prediction formulas, based on 
the method used to measure DLCO. In any case, the method used must be in compliance with 
the ATS/ERS guideline on DLCO measurements [ R06-2002 ], and the prediction formula 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 104 of 118
Proprietary confidential information © [ADDRESS_1155042]-03 (18.0) / Saved on: 10 Jul 2019appropriate for that method. Raw data (gas mixture, equation for the prediction of normal, further adjustments made if so), must be traced. 
Predicted DLCO corrected for haemoglobin (Hb) expressed in g x dL
-1[R06-2002] can be 
calculated as:
Predicted DLCO corrected for Hb = Predicted DLCO x (1.7Hb/(10.22+Hb)) for malesPredicted DLCO corrected for Hb= Predicted DLCO x (1.7Hb/(9.38+Hb)) for females
For decision on inclusion/exclusion, DLCO results from visit 1 will be corrected for 
haemoglobin (value obtained at visit 1) by [CONTACT_779]. 
For analysis of the trial data, DLCO results will be corrected for haemoglobin by [CONTACT_21657]. This means that the site has to enter the DLCO results without haemoglobin correction, in the eCRF, at applicable visits. 
There should be at least two acceptable tests that meet the repeatability requirement of either 
being within 3 mL CO (Standard Temperature and Pressure, Dry - STPD)•min-1 •mmHg-1 (or 1 mmol•min-1•kPa-1) of each other or within 10% of the highest value.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 105 of 118
Proprietary confidential information © [ADDRESS_1155043]-03 (18.0) / Saved on: 10 Jul 201910.5 ELIGIBILITY CONFIRMATION OF IPF DIAGNOSIS
Eligible are Patients with a clinical diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT 
Clinical Practice Guideline on the diagnosis of IPF as confirmed by [CONTACT_832084] [ADDRESS_1155044] HRCTs will be sent for central review by [CONTACT_832085]/ERS/JRS/ALAT guideline on the diagnosis of IPF and Fleischner Society white paper 
[R17-4075 ].
Patients with a centrally reviewed HRCT pattern qualifying as UIP or probable UIP are eligible for participation and are not required to have a surgical lung biopsy in the appropriate clinical context for the diagnosis of IPF.
Patients clinically suspected to have IPF with an HRCT pattern indeterminate for UIP, or 
suggesting an alternative diagnosis require historical (ie not taken for the purpose of this trial) surgical lung biopsy which will be reviewed locally (by [CONTACT_093]/local histo-pathologist). In these patients, specific combinations of HRCT patterns and histopathology patterns may still allow a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical 
Practice Guideline on the diagnosis of IPF. E.g. An HRCT pattern of "indeterminate for UIP"
in combination with a surgical lung biopsy with an histopathology pattern of “UIP or probable UIP” could qualify for inclusion.
Appropriate documentation at site for these cases is required. Copi[INVESTIGATOR_200929], 
histopathological assessments and resulting diagnosis are required in patient files.
IPF suspected1Histopathology pattern
UIP Probable UIP Indeterminate 
for UIPAlternative 
diagnosis
HRCT 
patternUIP IPF IPF IPF Non-IPF dx
Probable UIP IPF IPF IPF (Likely)2Non-IPF dx
Indeterminate IPF IPF (Likely)2Indeterminate3Non-IPF dx
Alternative 
diagnosisIPF(Likely)2/non-IPF 
dxNon-IPF dx Non-IPF dx Non-IPF dx
dx = diagnosis; HRCT = high-resolution computed tomography; IPF = idiopathic pulmonary fibrosis; UIP = usual interstitial 
pneumonia.       
(adapted from Figure 8 in R18-2794 )
Idiopathic pulmonary fibrosis diagnosis based upon HRCT and biopsy patterns.
1 “Clinically suspected of having IPF” = unexplained symptomatic or asymptomatic patterns of bilateral pulmonary fibrosis 
   on a chest radiograph or chest computed tomography, bibasilar inspi[INVESTIGATOR_274341], and age greater than 60 years.  
   (Middle-aged adults [.40 yr and ,60 yr], especially patients with risks for familial pulmonary fibrosis, can rarely present 
   with the otherwise same clinical scenario as the typi[INVESTIGATOR_832058] 60 years.)
2IPF is the likely diagnosis when any of the following features are present:
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 106 of 118
Proprietary confidential information © [ADDRESS_1155045]-03 (18.0) / Saved on: 10 Jul 2019∀ Moderate-to-severe traction bronchiectasis/bronchiolectasis (defined as mild traction 
bronchiectasis/bronchiolectasis in four or more lobes including the lingual as a lobe, or moderate to severe traction 
bronchiectasis in two or more lobes) in a man over age 50 years or in a woman over age 60 years
∀ Extensive (.30%) reticulation on HRCT and an age .70 years
∀ Increased neutrophils and/or absence of lymphocytosis in BAL fluid
∀ Multidisciplinary discussion reaches a confident diagnosis of IPF.
3 Indeterminate for IPF
∀ Without an adequate biopsy is unlikely to be IPF
∀ With an adequate biopsy may be reclassified to a more specific diagnosis after multidisciplinary discussion and/or 
additional consultation.
10.6 CREATININE CLEARANCE 
Calculation Name [CONTACT_657245]-EPI
[INVESTIGATOR_832059]:
Black or African American formulas:
Female with a serum creatinine value of ≤0.7 mg/dL
166 x (Serum Creatinine (mg/dL) / 0.7) -0.329x (0.993)age
Female with a serum creatinine value of >0.7 mg/dL
166 x (Serum Creatinine (mg/dL) / 0.7) -1.209x (0.993)age
Male with a serum creatinine value of ≤0.9 mg/dL
163 x (Serum Creatinine (mg/dL) / 0.9) -0.411x (0.993)age
Male with a serum creatinine value of >0.9 mg/dL163 x (Serum Creatinine (mg/dL) / 0.9) 
-1.209x (0.993)age
White, American Indian, Alaska Native, Asian, Native 
Hawaiian, Other Pacific Islander, Other formulas:
Female with a serum creatinine value of ≤0.7 mg/dL
144 x (Serum Creatinine (mg/dL) / 0.7) -0.329x (0.993)age
Female with a serum creatinine value of >0.7 mg/dL
144 x (Serum Creatinine (mg/dL) / 0.7) -1.209x (0.993)age
Male with a serum creatinine value of ≤0.9 mg/dL
141 x (Serum Creatinine (mg/dL) / 0.9) -0.411x (0.993)age
Male with a serum creatinine value of >0.9 mg/dL141 x (Serum Creatinine (mg/dL) / 0.9) 
-1.209x (0.993)age
Creatinine in mg/dL is rounded to 2 decimal places prior to 
applying the formula.mL/min/
1.73m²0
SI:
Serum creatinine in μmol/L will be rounded to zero decimal mL/min/
1.73m²0
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 107 of 118
Proprietary confidential information © [ADDRESS_1155046]-03 (18.0) / Saved on: [ADDRESS_1155047] and converted to mg/dL by [CONTACT_195914] 0.[ZIP_CODE]. This 
creatinine value in mg/dL will be rounded
to [ADDRESS_1155048]. This creatinine result will be used in
the GFR Conventional formulas listed above.
Limitations/Special 
Notes:Age is truncated to a whole number prior to performing the calculation.
Japanese formula will be used for Japanese patients.
10.7 EQUIVALENT DOSES OF CORTICOSTEROIDS
Table 10.7: 1 Equivalent Doses of Corticosteroids
Drug Equivalent dose (mg) Conversion factor
Prednisone 5 x 1
Prednisolone 5 x 1
Triamcinolone 4 x 1.25
6-Methylprednisolone 4 x 1.25
Dexamethasone 1 x 5
Betamethasone 0.75 x 6.7
16-Methylprednisolone 6 x 0.8
Fluocortalon 5 x 1
Cloprednol 3,75-5 x 1.0-1.5
Deflazacort 6 x 0.8
Cortisol (hydrocortisone) [ADDRESS_1155049] labelling /information.
Strong CYP3A4 inhibitors
10.8.1
Strong CYP 3A4 inhibitors:
∀boceprevir
∀clarithromycin
∀cobicistat
∀conivaptan
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 108 of 118
Proprietary confidential information © [ADDRESS_1155050]-03 (18.0) / Saved on: 10 Jul 2019∀diltiazem
∀idelalisib 
∀itraconazole
∀ketoconazole oral administration
∀nefazodone
∀nelfinafir
∀posaconazole
∀ritonavir
∀telaprevir
∀troleandomycin
∀voriconazole
Combinations of CYP 3A4 inhibitors:
∀danoprevir/ritonavir
∀elvitegravir/ritonavir
∀indinavir/ritonavir
∀lopi[INVESTIGATOR_054]/ritonavir
∀paritaprevir/ritonavir/ombitasvir/dasbuvir
∀saquinavir/ritonavir
∀tipranavir/ritonavir
Restricted PDE inhibitors 10.8.2
Compound Indication 
Non-selective
Theophylline (Theolair, Slo-Bid, Theo 24) Asthma and bronchoconstriction 
Aminophylline (Phyllocontin) Asthma and bronchoconstriction 
Oxtriphylline (Choledyl) Asthma and bronchoconstriction 
Dyphylline (inhibits PDE3, 4, 7, adenosine 2 receptors) (Dilor, Lufyllin) Asthma and bronchoconstriction 
Pentoxifylline (inhibits PDE4, 5, adenosine 2 receptors) (Trental, Pentoxil) Intermittent claudication 
Ibudilast (highest affinity for PDE10A, 
4, 11, 3) (Ketas, Pi[INVESTIGATOR_261936], Eyevinal) Asthma and dizziness related to cerebral 
infarction 
Allergic conjunctivitis 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 109 of 118
Proprietary confidential information © [ADDRESS_1155051]-03 (18.0) / Saved on: 10 Jul 2019Compound Indication 
Tofisopam (highest affinity for PDE4, 10, 3, 2) (Emandaxin, Grandaxin) Anxiety 
Dipyridamole (highest affinity for PDE8, 1, 3, 2, adenosine deaminase and ENT1) (Persantine) Post-operative thromboembolism 
PDE1
Vinpocetine (Cavinton) Cerebral vascular disorders and memory impairment 
PDE3
Cilostazol (Pletal, Ekistol) Intermittent claudication 
Milrinone (Primacor, Corotrope) Congestive heart failure 
Amrinone (Inamrinone, Inocor) Congestive heart failure 
Enoximone (Perfan) Congestive heart failure 
Olprinone (Coretec) Heart failure 
Pi[INVESTIGATOR_14854] (Acardi) Heart failure 
Anagrelide (also inhibits phospholipase A2) (Agrylin, Xagrid) Thrombocythaemia 
PDE4
Roflumilast (Daliresp, Daxas) Chronic obstructive pulmonary disease 
Apremilast (Otezla) Psoriasis and psoriatic disorders 
Crisaborole (Eucrisa) Moderate atopic dermatitis (patients >2 years old) 
Drotaverine (also inhibits L-type voltage-operated calcium channel) (No-Spa, Doverin) Functional bowel disorders; pain caused by [CONTACT_832086]10A
Papaverine (Pavabid, Pavagen) Visceral spasm, vasospasm and erectile dysfunction 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 110 of 118
Proprietary confidential information © [ADDRESS_1155052]-03 (18.0) / Saved on: [ADDRESS_1155053] errors from Table [IP_ADDRESS]:1 were used in the 
meta-analytic predictive (MAP) prior approach using the ‘gMap’ function from the RBest 
package. The used beta prior within the gMap function was defined as mean=0 and an SD=189. For the between-trial heterogeneity the tau prior was defined as mean=0 and SD=189/4. The graphical summary of this MAP analysis can be seen in Figure 10.9:1 below.
Figure 10.9:[ADDRESS_1155054] plot using the 5 historical studies.
In a next step the ‘automaxfit’ function is used to approximate the MAP prior with parametric 
density. The informative prior now consists of the following 3 components:
Component 1 Component 2 Component 3
Weight 0.5623 0.3714 0.0663
Mean -74.0307 -71.1166 -70.2132
SD 9.4634 24.8125 57.5269

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 111 of 118
Proprietary confidential information © [ADDRESS_1155055]-03 (18.0) / Saved on: [ADDRESS_1155056], a vaguely informative mixture component is added (Components 4 with weight=0.5, mean=-73 and SE=185.7). Finally, the prior is further down weighted by [CONTACT_832087] a factor of 1.7 to come to an effective sample size of around 20. This allows approximate 50% weight for new data collected in this study. The density plot of the final prior for the placebo group of patients not on SoC antifibrotic treatment can be found in Figure 10.9:2.
Figure 10.9:2 Density plot of the informative prior (black line) and its 4 components 
(coloured dashed lines).
The final informative prior consists of the following 4 components:
Component [ADDRESS_1155057] errors from Table [IP_ADDRESS]: 1 were used in the 
meta-analytic predictive (MAP) prior approach using the ‘gMap’ function from the RBest 
package. The used beta prior within the gMap function was defined as mean=0 and an 

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 112 of 118
Proprietary confidential information © [ADDRESS_1155058]-03 (18.0) / Saved on: 10 Jul 2019SD=186. For the between-trial heterogeneity the tau prior was defined as mean=0 and SD=186/4. The graphical summary of this MAP analysis can be seen in Figure 10.9:3 below.
Figure 10.9:[ADDRESS_1155059] plot using the 8 historical studies.
In a next step the‘automaxfit’ function is used to approximate the MAP prior with parametric 
density using the. The informative prior now consists of the following 3 components:
Component [ADDRESS_1155060], a vaguely informative mixture component is added (Components 4 with weight=0.5, mean=-19 and SE=183.6661). Finally, the prior is further down weighted by [CONTACT_832087] a factor of 2.1 to come to an effective sample size of around 20. This allows approximately 50% weight for new data collected in this study. The density plot of the final prior for the placebo group of patients on SoC antifibrotic treatment can be found in Figure 10.9:4 .

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 113 of 118
Proprietary confidential information © [ADDRESS_1155061]-03 (18.0) / Saved on: 10 Jul 2019Figure 10.9:4 Density plot of the informative prior (black line) and its 4 components (coloured dashed lines).
The final informative prior consists of the following 4 components:
Component 1 Component 2 Component 3 Component 4
Weight    0.2718   0.1966    0.0316   0.5
Mean -20.0640 -17.0402 -15.4163 -19
SD 16.2653 39.8255   87.6940 385.6988

Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 114 of 118
Proprietary confidential information © [ADDRESS_1155062]-03 (18.0) / Saved on: 10 Jul 201911. DESCRIPTION OF GLOBAL AMENDMENT(S)
11.[ADDRESS_1155063](s)BI 1015550
Title of protocol A randomised, double-blind, placebo-controlled parallel group  study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.
Global Amendment due to urgent safety reasons
Global Amendment X
Section to be changed Title
Description of change Dose and regimen deleted
Rationale for change To fullfill internal rules of disclosure. No change of the trial design.
Section to be changed Flowchart – footnote#11
Description of change Clarification about DNA and serum/plasma biobanking samples.
Rationale for change To correct a mistake which is already operationally corrected. The central laboratory builds laboratory kits for the trial according to this specification. To include the correction already described in a note to file prepared on 01 Apr 20. No changes to the procedures performed in the trial.
Section to be changed Table [IP_ADDRESS]
Description of change Addition of a missing letter and deletion of a coma.
Rationale for change Typo correction.
11.[ADDRESS_1155064](s)BI 1015550
Title of protocol A randomised, double-blind, placebo-controlled 
parallel group  study in IPF patients over 12 weeks 
evaluating efficacy, safety and tolerability of BI 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 115 of 118
Proprietary confidential information © [ADDRESS_1155065]-03 (18.0) / Saved on: 10 Jul 20191015550 taken orally.
Global Amendment due to urgent safety reasons
Global Amendment X
Section to be changed Flowchart – footnote#[ADDRESS_1155066] can be used for the trial.
Rationale for change To clarify this point. No change on the trial design.
Section to be changed Section 1.4.2 – table risks
Description of change Format change for some part which were in hidden text in version 1.0 :Risks associated with blood sampling, HRCT and lung measurements (PFT and DLCO) were missing as well as risk and mitigation plan for placebo use.
Rationale for change To make the whole text legible. Risks are described in the informed consent of the trial from the beginning.
Section to be changed Section 5.2.4 – Electrocardiogram recording
Description of change Correction of a mistake : no post dose ECG at V2 and not triplicate ECG expected.
Rationale for change To correct a mistake as this assessment was notexpected to be performed.
Section to be changedSection [IP_ADDRESS].[ADDRESS_1155067] a mistake.
Section to be changedSection 5.6.2 24 hours cough measurement.
Description of changeAddition of an inclusion criteria to enter the substudy. Clarification on the evaluations performed.
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 116 of 118
Proprietary confidential information © [ADDRESS_1155068]-03 (18.0) / Saved on: [ADDRESS_1155069](s)BI 1015550
Title of protocol A randomised, double-blind, placebo-controlled parallel group  study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.
Global Amendment due to urgent safety reasons
Global Amendment X
Section to be changed Flowchart + footnote #12, Section 3.1, Section 5.6, Section 5.6.1, 6.2.[ADDRESS_1155070] a better understanding of the toxicology profile of the molecule.
Section to be changed Table 1.4.2:1 Overview of trial related risks
Description of change Risk assessment due to COVID-19 pandemic 
situation added
Rationale for change New information on benefit/risk due to COVID-19 
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 117 of 118
Proprietary confidential information © [ADDRESS_1155071]-03 (18.0) / Saved on: [ADDRESS_1155072] by [CONTACT_832088] (BfArM)and leading Ethics Committee.
Section to be changed 3.3.3 Exclusion criteria
Description of change Addition of exclision criteria #27 (exclusion of patients with infection with SARS-CoV-2)
Rationale for change To exclude patients with potential additional risk due to SARS-CoV-2 infection.
Section to be changed [IP_ADDRESS] Discontinuation of trial treatment 
Description of change Addition of criteria to discontinue patients who meet AESI definition of hepatic injury 
Rationale for change Provision of additional guidance in case AESI definitions are fulfilled.
Section to be changed [IP_ADDRESS] Discontinuation of trial treatment 
Description of change Addition of criteria to discontinue patients who experience infection with SARS-CoV-[ADDRESS_1155073] shipments may be required in order to not interrupt treatment if a patient is not able to attend a visit due to COVID-19 related constraints. 
Section to be changed 5.2.3 Safety laboratory parameters
Description of change Correction to clarfy that ESR testing will be performed on-site not by [CONTACT_35970]. 
Rationale for change Correction and clarification.  
Section to be changed 6.1 Visit schedule, 6.2.2 Treatment period, 8.1Trial approval, patient information, informed consent
Description of change Specification that and how in exceptional circumstances (as e.g. in pandemic situations), when it is impossible to conduct study visits at the study site, study visits may be performed at 
patient’s home or remotely combined by [CONTACT_832089].
Rationale for change Experiences from the COVID-[ADDRESS_1155074] situation; to allow flexibility in visit conduct in case required due to pandemic or other exceptional
situations to ensure patients safety by [CONTACT_832090].
Boehringer Ingelheim 09 Sep 2020
BI Trial No.: 1305-0013
c29492723-04 Clinical Trial Protocol Page 118 of 118
Proprietary confidential information © [ADDRESS_1155075]-03 (18.0) / Saved on: [ADDRESS_1155076] by [CONTACT_832088] (BfArM)and leading Ethics Committee.